Breaking news releases, advisories, photos, and multimedia are available
at Tradeshownews.com,
Business Wire's trade show, conference, and event news resource.
|
Company:
|
|
Active Biotech AB
|
|
|
Ticker Symbol & Exchange:
|
|
ACTI (SEK)
|
|
|
Investor Relations Contact:
|
|
Mr. Göran Forsberg, VP IR & BD
|
|
|
Investor Relations Contact Phone:
|
|
46 46 19 11 54
|
|
|
Web:
|
|
www.activebiotech.com
|
|
|
Date of Presentation:
|
|
09/11/09
|
|
|
|
|
|
|
|
Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology
company with focus on autoimmune/inflammatory diseases and cancer.
Projects in pivotal phase are laquinimod, an orally administered
small molecule with unique immunomodulatory properties for the
treatment of multiple sclerosis, as well as ANYARA for use in cancer
targeted therapy, primarily of renal cancer. Further key projects in
clinical development comprise the three orally administered
compounds TASQ for prostate cancer, 57-57 for SLE and RhuDex for RA.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
Acucela Inc.
|
|
|
Investor Relations Contact:
|
|
Jennifer Beugelmans
|
|
|
Investor Relations Contact Phone:
|
|
(646) 596-7473
|
|
|
Web:
|
|
www.Acucela.com
|
|
|
Date of Presentation:
|
|
Wednesday, September 9, 2009
|
|
|
|
|
|
|
|
Acucela Inc. is a clinical-stage biotechnology company focused on
leveraging promising science in visual cycle modulation (VCM) to
develop new methods for treating blinding eye diseases that affect
tens of millions of people worldwide. The company's orally-delivered
VCM therapies, which selectively target cells within the retina to
protect visual acuity, have the potential to be used to treat
several devastating eye diseases, including dry age-related macular
degeneration (AMD), retinopathy of prematurity, Stargardt disease
and diabetic retinopathy. Acucela, with partner Otsuka
Pharmaceutical, is also developing Rebamipide ophthalmic suspension,
its Phase 3 program for dry eye. For more information, please visit
www.Acucela.com.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
Advanced Life Sciences
|
|
|
Ticker Symbol & Exchange:
|
|
ADLS OTC:BB
|
|
|
Investor Relations Contact:
|
|
Joe Camp
|
|
|
Investor Relations Contact Phone:
|
|
630-754-4352
|
|
|
Web:
|
|
www.advancedlifesciences.com
|
|
|
Date of Presentation:
|
|
Thursday, September 10 9:35 AM EDT
|
|
|
|
|
|
|
|
Advanced Life Sciences is a biopharmaceutical company engaged in the
discovery, development and commercialization of novel drugs in the
therapeutic areas of infection, cancer, respiratory diseases and
biodefense. For more information, please visit us on the web at
www.advancedlifesciences.com.
|
|
|
|
The company will presenting in the Hubbard Salon at The New York
Palace Hotel at 455 Madison Avenue in New York City. A live and
archived webcast of the call will be available at the company's
website.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
Advent Energy Ltd
|
|
|
Investor Relations Contact:
|
|
David Breeze
|
|
|
Investor Relations Contact Phone:
|
|
61 8 9328 8711, 0409 150 953
|
|
|
Web:
|
|
www.adventenergy.com.au
|
|
|
Date of Presentation:
|
|
Friday 11 September, 2009 at 2.50pm
|
|
|
|
|
|
|
|
Advent Energy Ltd is an unlisted Oil and Gas exploration company
with a strong asset portfolio containing near term production
opportunities and exploration upside. Advent is pursuing its option
to earn 85% in cornerstone project PEP 11 - offshore Sydney Basin.
|
|
|
|
The Sydney Basin is a proven petroleum basin with excellent
potential for the discovery of gas and oil. The recent demonstration
of an active hydrocarbon system with seeps reported in the offshore
area confirmed the presence of thermogenic hydrocarbon gas; this is
considered to occur in basins actively generating hydrocarbons and
/or that contain excellent migration pathways.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
Allon Therapeutics Inc.
|
|
|
Ticker Symbol & Exchange:
|
|
TSX:NPC
|
|
|
Investor Relations Contact:
|
|
Aaron Keay
|
|
|
Investor Relations Contact Phone:
|
|
(604) 323-6911
|
|
|
Web:
|
|
www.allontherapeutics.com
|
|
|
Date of Presentation:
|
|
09/09/09
|
|
|
|
|
|
|
|
Allon Therapeutics Inc. is a clinical-stage biotechnology company
focused on developing the first drugs that impact the progression of
neurodegenerative diseases. Allon's drug davunetide has demonstrated
human efficacy in amnestic mild cognitive impairment, a precursor to
Alzheimer's disease, and schizophrenia-related cognitive impairment.
Allon has Phase II human efficacy programs pursuing large
underserved markets: Alzheimer's disease, frontotemporal dementia,
and schizophrenia-related cognitive impairment. The Company is
listed on the Toronto Stock Exchange under the trading symbol "NPC"
(Neuro Protection CompanyTM) and based in Vancouver. For additional
information please visit the Company's website:
www.allontherapeutics.com.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
AllTranz Inc.
|
|
|
Investor Relations Contact:
|
|
Clint Dederick
|
|
|
Investor Relations Contact Phone:
|
|
513-252-7894
|
|
|
Web:
|
|
www.alltranz.com
|
|
|
Date of Presentation:
|
|
09/11/09
|
|
|
|
|
|
|
|
AllTranz Inc. is a specialty pharmaceutical company based in
Lexington, KY. AllTranz will be a leader in the advancement of pain
therapy by developing innovative prodrug strategies delivered via
unique dermal delivery solutions to treat a variety of pain
disorders. AllTranz leverages proprietary technology to modify
existing chemical entities with proven clinical outcomes to produce
important new pharmaceutical products that extend patent franchises.
The Company's expertise in formulation, prodrug development, and
dermal delivery products exploits the opportunity for lower risk
development pathways to significant new drugs. We are currently
looking to close on strategic alliances and a Series B round.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
Altairnano, Inc.
|
|
|
Ticker Symbol & Exchange:
|
|
ALTI
|
|
|
Investor Relations Contact:
|
|
Todd Carney
|
|
|
Investor Relations Contact Phone:
|
|
775-858-3727
|
|
|
Web:
|
|
www.altairnano.com
|
|
|
Date of Presentation:
|
|
September 9, 2009; 9:25am
|
|
|
|
|
|
|
|
Headquartered in Reno, NV, Altairnano is a leading provider of
energy storage systems for clean, efficient power and energy
management. Designed for power-dependent applications, Altairnano's
advanced lithium-ion energy storage systems and batteries are
responding to changing demands in energy generation, utilization,
and policy. Whether it's reducing dependencies on traditional
generation facilities, reducing carbon emissions, or accelerating
the adoption of renewable integration and alternative-fuel vehicles,
Altairnano helps achieve sustainable, and economically sensible,
power and energy management practices.
|
|
|
|
With proprietary technologies, proven market acceptance, and
production scalability, Altairnano is uniquely positioned to help
solve the challenges and opportunities of an energy-focused economy.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
Altea Therapeutics
|
|
|
Investor Relations Contact:
|
|
Angela Walsh
|
|
|
Investor Relations Contact Phone:
|
|
404-835-6430
|
|
|
Web:
|
|
www.alteatherapeutics.com
|
|
|
Date of Presentation:
|
|
9/11/09 at 2p
|
|
|
|
|
|
|
|
Altea Therapeutics is a clinical-stage pharmaceutical company with a
proprietary platform technology applicable to transdermal delivery
of biologicals and water soluble drugs that are typically
administered by needle injection or infusion. Altea Therapeutics is
developing and commercializing initial products with pharmaceutical
industry, including two products with Amylin/Lilly (exenatide) and
Hospira (undisclosed). Altea Therapeutics is also developing
transdermal patches delivering basal insulin, PTH and fentanyl
citrate that are available for partnering. Altea Therapeutics is
undertaking several collaborations with pharmaceutical companies to
assess the feasibility of transdermal delivery of their drugs, each
with potential to become a full development and commercialization
partnership.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
American Lorain Corporation
|
|
|
Ticker Symbol & Exchange:
|
|
OTC BB: ALRC
|
|
|
Investor Relations Contact:
|
|
Alan Jin, CFO
|
|
|
Investor Relations Contact Phone:
|
|
Crocker Coulson, CCG, 1(646) 213-1915
|
|
|
Web:
|
|
www.americanlorain.com
|
|
|
Date of Presentation:
|
|
10:25AM on Wed. Sept. 9, 2009
|
|
|
|
|
|
|
|
American Lorain Corporation, ("American Lorain" , the "Company" ) is a
leading processed foods company operating in China through its four
direct and indirect subsidiaries and one leased factory. The Company
produces and sells chestnuts, convenience foods, and frozen, canned,
and bulk food prodcucts to both domestic and international
customers. The Company's current product portfolio includes 234
products and sales channels reach 26 provinces and administrative
regions in China as well as 42 foreign countries.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
[ANTARES PHARMA INC.]
|
|
|
Ticker Symbol & Exchange:
|
|
(NYSE AMEX: AIS)
|
|
|
Investor Relations Contact:
|
|
Lisa Wilson
|
|
|
Investor Relations Contact Phone:
|
|
(917) 543-9932
|
|
|
Web:
|
|
www.antarespharma.com
|
|
|
Date of Presentation:
|
|
Thursday, September 10th
|
|
|
|
|
|
|
|
Antares Pharma is a revenue-generating, product-focused company that
has developed proprietary drug-delivery platforms, two of which now
include FDA-approved products. Our products improve safety and
efficacy profiles by minimizing dosing and reducing side effects.
|
|
|
|
Antares was formed in 2001 when Medi-Ject Corporation (a device
company) merged with Permatec Holding AG (developer of ATD gel
transdermal delivery systems). Presently we have broad approval for
our needle-free device in the US for insulin and in Europe, Asia and
the US for human growth hormone. In addition, we have a disposable
pressure assisted auto injector product which uses a disposable
single use small gauge needle for unit dose injectable drugs; we
have recently added a disposable multi-use pen injector.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
Antisoma
|
|
|
Ticker Symbol & Exchange:
|
|
LSE: ASM; USOTC: ATS
|
|
|
Investor Relations Contact:
|
|
Dr Daniel Elger
|
|
|
Investor Relations Contact Phone:
|
|
44 7909 915 068
|
|
|
Web:
|
|
www.antisoma.com
|
|
|
Date of Presentation:
|
|
September 10th,
|
|
|
|
|
|
|
|
Based in London, UK, and Cambridge, MA, Antisoma is focused on the
development and commercialization of new treatments for cancer.
Antisoma has a worldwide development and marketing partnership with
Novartis for ASA404, a potential blockbuster Tumor-Vascular
Disrupting Agent in phase III development for lung cancer. Antisoma
retains marketing rights to its other pipeline products, including a
further phase III drug, AS1413, which is in a pivotal phase III
trial for secondary AML. The Company intends to sell these products
itself in the US whilst seeking partnerships for marketing in other
territories. Please visit www.Antisoma.com for further information
about Antisoma.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
Arena Resources, Inc.
|
|
|
Ticker Symbol & Exchange:
|
|
ARD NYSE
|
|
|
Investor Relations Contact:
|
|
Bill Parsons
|
|
|
Investor Relations Contact Phone:
|
|
(480) 947-1589
|
|
|
Web:
|
|
www.arenaresourcesinc.com
|
|
|
Date of Presentation:
|
|
09/09/09
|
|
|
|
|
|
|
|
Arena Resources, Inc. (NYSE: ARD) is an Oklahoma-based oil and gas
exploration, development and production company with current
operations in Texas, Oklahoma, Kansas and New Mexico. Founded in
2000, the experienced management team has aggressively sought to
acquire select properties in their "back yard" which provides
immediate positive cash flow and development opportunities for
future years. As of December 31, 2008, the company has an estimated
65.6 million BOE's (barrel of oil equivalents) and an estimated
$651.6 million* in PV-10 (future net revenues discounted 10%).
|
|
|
|
*Independent audit prepared 12/31/08 using $38.30 per barrel of oil
/ $4.35 per mcf of natural gas.
|
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
ARIAD Pharmaceuticals, Inc.
|
|
|
Ticker Symbol & Exchange:
|
|
NASDAQ: ARIA
|
|
|
Investor Relations Contact:
|
|
Maria E. Cantor
|
|
|
Investor Relations Contact Phone:
|
|
617-621-2208
|
|
|
Web:
|
|
www.ariad.com
|
|
|
Date of Presentation:
|
|
09/09/09
|
|
|
|
|
|
|
|
ARIAD's vision is to transform the lives of cancer patients with
breakthrough medicines. The Company's mission is to discover,
develop and commercialize small-molecule drugs to treat cancer in
patients with the greatest and most urgent unmet medical need -
aggressive cancers where current therapies are inadequate. ARIAD's
lead product candidate, ridaforolimus, is an investigational mTOR
inhibitor in Phase 3 clinical development in patients with advanced
sarcomas and is being developed in collaboration with Merck & Co.,
Inc. ARIAD's second product candidate, AP24534, is an
investigational multi-targeted kinase inhibitor in Phase 1 clinical
development in patients with hematological cancers, including CML.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
AspenBio Pharma, Inc.
|
|
|
Ticker Symbol & Exchange:
|
|
APPY
|
|
|
Investor Relations Contact:
|
|
Ron Liolios Group
|
|
|
Investor Relations Contact Phone:
|
|
949-574-3860
|
|
|
Web:
|
|
www.aspenbiopharma.com
|
|
|
Date of Presentation:
|
|
09/09/09
|
|
|
|
|
|
|
|
AspenBio Pharma is an emerging biotechnology company dedicated to
the discovery, development and commercialization of novel products
that address unmet diagnostic and therapeutic needs in both human
and animal health.
|
|
|
|
The company's AppyScore blood-based test addresses the difficult
challenge of diagnosing human appendicitis in the hospital emergency
department. The company is also advancing unique therapeutic
proteins designed to improve reproduction in non-companion animals
of economic importance.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
Austral Gold Limited
|
|
|
Ticker Symbol & Exchange:
|
|
AGD
|
|
|
Investor Relations Contact:
|
|
Mark Bethwaite
|
|
|
Investor Relations Contact Phone:
|
|
61 4199 34860
|
|
|
Web:
|
|
www.australgold.com.au
|
|
|
Date of Presentation:
|
|
Friday 11 September, 2009
|
|
|
|
|
|
|
|
Austral Gold Limited (ASX AGD) is an Australian-based exploration
junior. The company is advancing its 100%-owned Guanaco gold, copper
and silver project in Chile, where it is reviewing a Feasibility
Study to restart mining operations.
|
|
|
|
Guanaco is located 220 kilometres southeast of Antofagasta and gold
has been mined in the area since 1886. Following Austral Gold's
successful drill campaign in 2008, total resources have been
increased to 904,361oz of gold and 3,930,309oz of silver.
|
|
|
|
Austral Gold has exploration prospects in Australia and in
Argentina, in addition to its flagship project in Chile.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
Avalon Rare Metals Inc.
|
|
|
Ticker Symbol & Exchange:
|
|
TSX:AVL, OTCQX:AVARF
|
|
|
Investor Relations Contact:
|
|
Don Bubar / Virginia Morgan
|
|
|
Investor Relations Contact Phone:
|
|
416-364-4938
|
|
|
Web:
|
|
www.avalonraremetals.com
|
|
|
Date of Presentation:
|
|
09/11/09
|
|
|
|
|
|
|
|
Avalon Rare Metals Inc. (TSX:AVL, OTCQX:AVARF) is a mineral
exploration and development company focused on rare metals deposits
in Canada. Its flagship project, 100%-owned Lake Zone Deposit, Thor
Lake, NWT, is emerging as one of the largest undeveloped rare earth
elements ("REE" ) resources in the world. Its exceptional enrichment
in the more valuable 'heavy' REE, which are key to enabling advances
in green energy technology and other growing high-tech applications,
is one of the few potential sources of these critical elements
outside of China, currently the source of 95% of world supply.
Social responsibility and environmental stewardship are corporate
cornerstones.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
Avanir Pharmaceuticals, Inc.
|
|
|
Ticker Symbol & Exchange:
|
|
AVNR / NASDAQ
|
|
|
Investor Relations Contact:
|
|
Eric Benevich or Brenna Mullen
|
|
|
Investor Relations Contact Phone:
|
|
(949)389-6700
|
|
|
Web:
|
|
www.avanir.com
|
|
|
Date of Presentation:
|
|
September 10, 2009 at 10:50am ET
|
|
|
|
|
|
|
|
Avanir Pharmaceuticals, Inc. is a biopharmaceutical company focused
on acquiring, developing, and commercializing novel therapeutic
products for the treatment of central nervous system disorders.
Avanir's lead product candidate, Zenvia , is in Phase III
development for the treatment of pseudobulbar affect (PBA) and
diabetic peripheral neuropathic (DPN) pain.
|
|
|
|
Recently, Avanir announced positive results from the confirmatory
Phase III STAR trial where both doses of Zenvia demonstrated a
significant reduction of PBA episode rates compared to placebo. The
Company plans to submit a complete response to the PBA approvable
letter and anticipates an FDA approval decision in the second half
of 2010.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
AXION POWER INTERNATIONAL INC
|
|
|
Ticker Symbol & Exchange:
|
|
OTC BB: AXPW
|
|
|
Investor Relations Contact:
|
|
Rudy Barrio
|
|
|
Investor Relations Contact Phone:
|
|
212.691.8087
|
|
|
Web:
|
|
www.axionpower.com
|
|
|
Date of Presentation:
|
|
09/10/09
|
|
|
|
|
|
|
|
Axion's principal, potentially disruptive technology is its PbC
battery, developed to play an important role in the burgeoning
electric, micro- and mild-hybrid car markets, defense applications,
utility and industrial energy storage, renewable energy (wind,
solar), grid-related (uninterruptible power, load-leveling, peak
shaving) and other emerging markets. Among the advantages of Axion's
new PbC technology, which won a Frost and Sullivan Innovation Award
for North America, are efficiency, sustainability, manufacturability
and ease of recycling. PbC technology uses nanoporous activated
carbon electrode assemblies to replace the simple lead-based
negative electrodes used by other lead-acid battery manufacturers.
|
|
|
|
Axion is working with Exide Technologies, one of the world's largest
producers and recyclers of lead-acid batteries.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
AZURE DYNAMICS
|
|
|
Ticker Symbol & Exchange:
|
|
OTCQX:AZDDF
|
|
|
Investor Relations Contact:
|
|
Michael Mason
|
|
|
Investor Relations Contact Phone:
|
|
212.691.8087
|
|
|
Web:
|
|
www.azuredynamics.com
|
|
|
Date of Presentation:
|
|
09/11/09
|
|
|
|
|
|
|
|
Azure Dynamics is a leading innovator in the development of
environmentally friendly and cost effective hybrid electric and
electric technologies for commercial vehicles.
|
|
|
|
The Company supplies hybrid electric vehicle (HEV) and electric
vehicle (EV) control and powertrain systems for delivery fleets,
utility vehicles, and shuttle buses. Azure has an established
portfolio of proprietary component products that compliments its
core technical skills and makes use of an extensive supplier base to
offer complete powertrain solutions to its target market.
|
|
|
|
Azure has partnered with seven of the leading bus body manufacturers
in the US and Canada and with 27 Ford commercial truck dealerships
in key markets across North America. These partnerships give Azure
significant market presence and expanded sales and service
capabilities.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
B.O.S. Better Online Solutions Ltd.
|
|
|
Ticker Symbol & Exchange:
|
|
Nasdaq:BOSC
|
|
|
Investor Relations Contact:
|
|
Zipi Weinreich, zipiw@boscom.com
|
|
|
Investor Relations Contact Phone:
|
|
972-3-9541008
|
|
|
Web:
|
|
www.boscom.com
|
|
|
|
|
|
|
|
B.O.S. Better Online Solutions Ltd (Nasdaq:BOSC) is a leading
provider of RFID, Mobile and Supply Chain solutions to global
enterprises. BOS' proprietary BOSERVER, BOSaNova, RFID, Mobile and
supply chain offerings are being used to improve the efficiency of
enterprise logistics and organizational monitoring and control
systems of over 2000 customers worldwide. With BOS solutions,
companies are enhancing the automation of various aspects of their
supply chain, improving asset tracking, and managing real-time
business data, all crucial to improving margins in today's
competitive marketplace.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
BELLUS Health Inc.
|
|
|
Ticker Symbol & Exchange:
|
|
TSX: BLU
|
|
|
Investor Relations Contact:
|
|
Michelle Stein
|
|
|
Investor Relations Contact Phone:
|
|
450 680 4573
|
|
|
Web:
|
|
www.bellushealth.com
|
|
|
Date of Presentation:
|
|
09/11/09
|
|
|
|
|
|
|
|
BELLUS Health is a global health company focused on the development
and commercialization of products to provide innovative health
solutions to address critical unmet needs. The Company's
pharmaceutical strategy includes the development of investigational
product candidates for the treatment of Amyloid A amyloidosis, Type
II diabetes and certain features of metabolic syndrome, and
Alzheimer's disease. BELLUS Health's pipeline contains promising
therapeutic products at various stages of development that have the
potential to be large growth drivers. BELLUS Health's wholly owned
subsidiary, OVOS Natural Health, is expected to generate revenue and
profit through the marketing of branded nutraceutical products.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
Bio-Bridge Science, Inc.
|
|
|
Ticker Symbol & Exchange:
|
|
OTCBB: BGES
|
|
|
Investor Relations Contact:
|
|
Chris Young
|
|
|
Investor Relations Contact Phone:
|
|
630-928-0869
|
|
|
Web:
|
|
www.bio-bridge-science.com
|
|
|
Date of Presentation:
|
|
09/11/09
|
|
|
|
|
|
|
|
Bio-Bridge Science, a biotechnology company, focuses on the
commercial development of biological products for the prevention
and treatment of human diseases, and production materials in
producing vaccines. Its products under development include an HIV
vaccine, a vaccine to prevent AIDS; a colon cancer therapeutic
vaccine; and an HPV vaccine to prevent cervical cancer. It holds
license for the HIV and colon cancer vaccine technology in China,
Japan, and the US. It also sells bovine serum, a vaccine
production material, and expects to form a joint venture to
produce cell culture medium, another vaccine production material,
in the near future.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
BioSante Pharmaceuticals, Inc.
|
|
|
Ticker Symbol & Exchange:
|
|
BPAX: NASDAQ
|
|
|
Investor Relations Contact:
|
|
Phillip Donenberg
|
|
|
Investor Relations Contact Phone:
|
|
847-478-0500 ext 100
|
|
|
Web:
|
|
www.biosantepharma.com
|
|
|
Date of Presentation:
|
|
09/10/09
|
|
|
|
|
|
|
|
BioSante is a specialty pharmaceutical company focused on developing
products for female sexual health, menopause, contraception and male
hypogonadism. BioSante's lead products include LibiGel (transdermal
testosterone gel) in Phase III clinical development by BioSante
under a U.S. Food and Drug Administration (FDA) SPA (Special
Protocol Assessment) for the treatment of female sexual dysfunction
(FSD), and Elestrin (estradiol gel) developed through FDA approval
by BioSante, indicated for the treatment of moderate-to-severe
vasomotor symptoms associated with menopause, currently marketed in
the U.S. Also in development are Bio-T-Gel , a testosterone gel for
male hypogonadism, and an oral contraceptive in Phase II/III
clinical development.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
Biotie Therapies Corp.
|
|
|
Ticker Symbol & Exchange:
|
|
BTHIV NASDAQ OMX
|
|
|
Investor Relations Contact:
|
|
Dr Thomas Taapken
|
|
|
Investor Relations Contact Phone:
|
|
358 2 274 8900
|
|
|
Web:
|
|
www.biotie.com
|
|
|
Date of Presentation:
|
|
Wednesday September 9, 2009
|
|
|
|
|
|
|
|
Biotie is a drug discovery and development company focused on
central nervous system and inflammatory diseases. It has a broad
range of innovative small molecule and biological drug candidates at
different stages of clinical and pre-clinical development. Biotie's
products address diseases with high unmet medical need and
significant market potential, including addiction and psychotic
disorders, rheumatoid arthritis, psoriasis and chronic obstructive
pulmonary disease (COPD). The most advanced product, nalmefene for
alcohol dependence, is currently in phase III clinical development
by licensing partner H. Lundbeck A/S.
|
|
|
|
The commercial value of the pipeline has been demonstrated through
existing alliances with top-tier global pharmaceutical companies
such as Lundbeck, Roche and Wyeth.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
Blaze Energy Ltd.
|
|
|
Investor Relations Contact:
|
|
Kevin Donegan
|
|
|
Investor Relations Contact Phone:
|
|
403-264-0877 ext. 814
|
|
|
Web:
|
|
www.blazeenergy.com
|
|
|
Date of Presentation:
|
|
September 9, 2009 4:55PM
|
|
|
|
|
|
|
|
Blaze Energy Ltd., formed in 1995, is an entrepreneurial Canadian
private oil and natural gas exploration and development company with
midstream operations. Blaze is producing 650 BOE/d from its core
assets in West Central Alberta, Canada, and unlike many of its
junior peers, it owns, operates and processes third party natural
gas through its 185 mmcf/d plant located in Brazeau, Alberta. Blaze
is adding value through:
|
|
|
|
|
|
|
i) continuing to drill its prolific, multi-zone, low-density,
liquids rich core area with exploration upside;
|
|
|
|
|
|
|
ii) evaluating the resource potential of its core area as
competitors continue to make horizontal drilling announcements;
|
|
|
|
|
|
|
iii) increasing third party natural gas processing;
|
|
|
|
|
|
|
iv) technical feasibility established, commercial feasibility under
review of natural gas storage and enhanced oil recovery scheme.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
Boots & Coots, Inc.
|
|
|
Ticker Symbol & Exchange:
|
|
NYSE Amex: WEL
|
|
|
Investor Relations Contact:
|
|
Jennifer Tweeton
|
|
|
Investor Relations Contact Phone:
|
|
281-931-8884
|
|
|
Web:
|
|
www.boots-coots.com
|
|
|
Date of Presentation:
|
|
09/09/09, 2:50 PM
|
|
|
|
|
|
|
|
Boots & Coots provides a suite of integrated pressure control
services to oil and gas companies around the world. Boots & Coots'
services include well intervention services designed to enhance oil
and gas productions. These services consist primarily of hydraulic
workover and snubbing services. Boots & Coots' equipment services
segment provides high pressure, high temperature rental tools. The
company's pressure control services are designed to reduce the
number and severity of critical events such as well fires, blowouts
or other incidences due to loss of control at the well. This segment
includes the company's Safeguard prevention and emergency response
services.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
Bow Energy Limited
|
|
|
Ticker Symbol & Exchange:
|
|
BOW:ASX
|
|
|
Investor Relations Contact:
|
|
John De Stefani
|
|
|
Investor Relations Contact Phone:
|
|
(617) 3303 0675
|
|
|
Web:
|
|
www.bowenergy.com.au
|
|
|
Date of Presentation:
|
|
09/10/09
|
|
|
|
|
|
|
|
Bow Energy Limited is a leading energy company based in Brisbane,
Australia. It has a highly prospective portfolio of coal seam gas
(CSG) acreage in Queensland's Bowen and Surat Basins, strategically
located adjacent to established CSG projects and near the planned
Gladstone liquefied natural gas projects. Bow has over 660 PJ of 3P
certifed gas reserves. Bow also has conventional oil projects in the
Cooper, Eromanga and Surat-Bowen Basins. Bow is listed on the
Australian Securities Exchange under the ticker code of BOW, with
market capitalization of approximately AUD$280 million (as of August
17, 2009). Refer to www.bowenergy.com.au.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
BTU International, Inc
|
|
|
Ticker Symbol & Exchange:
|
|
BTUI - NASDAQ
|
|
|
Investor Relations Contact:
|
|
Bill Monigle
|
|
|
Investor Relations Contact Phone:
|
|
941-497-1622
|
|
|
Web:
|
|
www.btu.com
|
|
|
Date of Presentation:
|
|
09/10/09
|
|
|
|
|
|
|
|
BTU International is a market-leading, global supplier of advanced
thermal processing equipment and processes to the alternative energy
and electronics assembly markets. BTU equipment and know-how are
used in solar cell, nuclear fuel and fuel cell manufacturing as well
as in the production of printed circuit board assemblies and
semiconductor packaging. Providers of alternative energy solutions
appreciate BTU's highly efficient products enabling lower cost per
watt solutions, whereas semiconductor and electronics manufacturers
look for BTU's high throughput, high yield manufacturing tools and
technologies that help them remain competitive. BTU has operations
in Massachusetts, USA and Shanghai, China with direct sales and
service worldwide.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
Cangene Corporation
|
|
|
Ticker Symbol & Exchange:
|
|
CNJ on TSX
|
|
|
Investor Relations Contact:
|
|
Ms. Jean Compton
|
|
|
Investor Relations Contact Phone:
|
|
416-675-8280
|
|
|
Web:
|
|
www.cangene.com
|
|
|
Date of Presentation:
|
|
09/11/09
|
|
|
|
|
|
|
|
Cangene is a profitable and fully integrated developer and
manufacturer of immune therapeutics and recombinant
biopharmaceuticals, primarily targeting infectious disease and
biodefence applications. Most of Cangene's products are
hyperimmunes-purified antibody products that are specific for
targets such as hepatitis B, botulism, and anthrax. With nearly 30
years of experience making its lead drug, WinRho SDF, manufacturing
capability is one of Cangene's key strengths. The Company has
operations in Manitoba and Ontario in Canada, and California,
Maryland and Florida in the U.S. Most of its 700 employees work in
Winnipeg or at its Baltimore subsidiary, Chesapeake Biological
Laboratories, Inc.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
Celladon Corporation
|
|
|
Investor Relations Contact:
|
|
Rebecque Laba
|
|
|
Investor Relations Contact Phone:
|
|
858-366-4288
|
|
|
Web:
|
|
www.celladon.net
|
|
|
Date of Presentation:
|
|
Friday, September 11th at 2:25p
|
|
|
|
|
|
|
|
Celladon is a privately held biotechnology company founded with the
goal of becoming the leader in developing molecular therapies for
the treatment of heart failure. Our products target the key enzyme
deficiency in advanced heart failure, SERCA2a, which regulates
calcium cycling and contractility in heart muscle cells. Our first
product candidate, MYDICAR, delivers the gene for the SERCA2a
enzyme and is currently being tested in Phase 1 and 2 clinical
trials. We are also developing small molecule activators of SERCA2a
for acute heart failure.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
Chariot Resources Limited
|
|
|
Ticker Symbol & Exchange:
|
|
CHD:TSX
|
|
|
Investor Relations Contact:
|
|
Forbes West
|
|
|
Investor Relations Contact Phone:
|
|
416-203-2200/forbes@sherbournegroup.ca
|
|
|
Web:
|
|
www.chariotresources.com
|
|
|
Date of Presentation:
|
|
09/10/09
|
|
|
|
|
|
|
|
Chariot Resources (CHD:TSX) is developing its 70% owned Mina Justa
deposit in Peru, one of South America's premier new copper projects.
During the 11.5 year mine life, vat leaching will produce 1.06
billion pounds of cathode copper, and the concentrator will produce
concentrates containing 1.32 billion pounds of payable copper, and
16.0 million ounces of payable silver.The Environmental and Social
Impact Assessment is scheduled to be submitted to regulators in
August. Permitting processes will run in parallel, so approval of
the ESIA is followed closely by the granting of permits to make the
robust Mina Justa Project "shovel ready" .
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
China Advanced Construction Materials
|
|
|
Ticker Symbol & Exchange:
|
|
CADC: OTCBB
|
|
|
Investor Relations Contact:
|
|
David Waldman
|
|
|
Investor Relations Contact Phone:
|
|
212-671-1020
|
|
|
Web:
|
|
www.china-acm.com
|
|
|
Date of Presentation:
|
|
09/10/09
|
|
|
|
|
|
|
|
China ACM, founded in 2002 and based in Beijing, China, is a leading
producer of advanced construction materials for large scale
commercial, residential, and infrastructure developments. The
company is primarily focused on producing and supplying a wide range
of advanced ready-mix concrete materials for highly technical, large
scale, and environmental construction projects. The company also
aims to develop and produce new and innovative environmentally
conscious construction materials.
|
|
|
|
China ACM provides materials and services through its seven
ready-mix concrete plant network covering Beijing metropolitan area.
China ACM owns one plant, leases two plants and has technical
services and preferred procurement agreements with four other
independently-owned plants.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
China Auto Logicstics Inc.
|
|
|
Ticker Symbol & Exchange:
|
|
CALI Nasdaq
|
|
|
Investor Relations Contact:
|
|
Ken Donenfeld
|
|
|
Investor Relations Contact Phone:
|
|
(212) 425-5700
|
|
|
Web:
|
|
www.chinaautologisticsinc.com/
|
|
|
Date of Presentation:
|
|
Sep 10, 2009 from 3:40 - 4:05 PM
|
|
|
|
|
|
|
|
China Auto Logistics Inc. is one of China's top importers of luxury
cars and the developer of leading websites for buyers and sellers of
imported and domestic automobiles. The Company is also China's
leading "one stop" provider of logistical services and financing to
imported car dealers nationwide. The Company has made the strategic
decision to deemphasize imported auto unit sales in favor of
expanding its new, highly profitable domestic auto websites,
currently in 12 cities and accessible through its national website,
www.at160.com, launched in May, 2009. Already contributing
significantly to profits, the Company believes further expansion of
its websites, including new web-based auto-related services, will
drive future growth.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
China Biologic Products, Inc.
|
|
|
Ticker Symbol & Exchange:
|
|
CBPO.OB
|
|
|
Investor Relations Contact:
|
|
Crocker Coulson
|
|
|
Investor Relations Contact Phone:
|
|
646 213 1915
|
|
|
Web:
|
|
http://www.chinabiologic.com/
|
|
|
Date of Presentation:
|
|
09/10/09
|
|
|
|
|
|
|
|
China Biologic Products, Inc. (CBPO.OB) through its indirect
majority-owned subsidiary, Shandong Taibang Biological Products Co.
Ltd. ("Taibang" ) and Chongqing Dalin Biologic Technologies Co., Ltd.
("Dalin" ) and its equity investment in Xi'an Huitian Blood Products
Co., Ltd. ("Huitian" ), is currently the largest non-state-owned
plasma-based biopharmaceutical company approved by the Chinese
government. The company is a fully integrated biologic products
company with plasma collection, production and manufacturing,
research and development, and commercial operations. Blood products
are biological products used in biological active preparation to
collect healthy blood for raw materials, which are manufactured
through biological processes or separation and purification
technologies.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
China-Biotics, Inc.
|
|
|
Ticker Symbol & Exchange:
|
|
CHBT (NASDAQ GM)
|
|
|
Investor Relations Contact:
|
|
Crocker Coulson
|
|
|
Investor Relations Contact Phone:
|
|
1 646-213-1915
|
|
|
Web:
|
|
www.chn-biotics.com
|
|
|
Date of Presentation:
|
|
09/11/09
|
|
|
|
|
|
|
|
Headquarterd in Shanghai, China-Biotics was founded in 1999 and is
one of China's largest suppliers of probiotics. Probiotics are
beneficial live bacteria used in dietary supplements and food
additives to improve intestinal health and digestion. The Company's
product portfolio contains live microbials made with proprietary
technology. These products are sold over-the-counter under the
"Shining" brand through large distributors to more than 1,000
pharmacies and 100 supermarkets in Shanghai, Jiangsu, Zhejiang and
Hong Kong.. Shining is one of the most recognized brands in
Shanghai. There is significant demand for probiotics for use in bulk
additive market, which is currently met by imports. China-Biotics
has built up a new plant with 150 metric ton annual capacity that
will increase its production capacity manyfold to capture this market
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
China Carbon Graphite Group
|
|
|
Ticker Symbol & Exchange:
|
|
CHGI - OTCBB
|
|
|
Investor Relations Contact:
|
|
Capital Group Communications
|
|
|
Investor Relations Contact Phone:
|
|
Kevin Fickle /Mark Bernhard -415-332-7200
|
|
|
Web:
|
|
chinacarboninc.com
|
|
|
Date of Presentation:
|
|
Thursday, September 10th, 12:30PM
|
|
|
|
|
|
|
|
One of China's largest producers and wholesale suppliers of fine
grain and high purity graphite. 2008 Earnings $.21 share.
|
|
|
|
|
|
|
Recent Events:
|
|
|
|
|
Retired 5,875,000 warrants through issuance of 887,500 common
shares. 14,672,970 common shares outstanding.
|
|
|
|
|
|
|
Final approval & funding of $26,000,000 (US) loan from Chinese
Central Government's economic stimulus plan expected within 60 days.
Company will double production capacity to 30,000 metric tons
annually, develop and produce nuclear grade graphite for 40 nuclear
reactors Chinese government building by 2015. Each reactor requires
10,000 metric tons of nuclear graphite @ $1,500 ton averaging
$150,000,000 (US).
|
|
|
|
|
|
|
Company actively seeking same sector acqusitions in China.
|
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
China Energy Recovery, Inc.
|
|
|
Ticker Symbol & Exchange:
|
|
CGYV.OB
|
|
|
Investor Relations Contact:
|
|
Jim Blackman
|
|
|
Investor Relations Contact Phone:
|
|
713-256-0369
|
|
|
Web:
|
|
http://www.chinaenergyrecovery.com
|
|
|
Date of Presentation:
|
|
September 10, 2009 (Thursday)
|
|
|
|
|
|
|
|
CER is an international leader in designing, manufacturing and
installing waste heat energy recovery systems which provide
facilities with greater energy efficiency. The company's primary
focus is on the Chinese market. CER's technology captures
industrial waste energy to produce low-cost electrical power,
enabling industrial manufacturers to reduce their energy costs,
shrink their emissions footprint, and generate sellable emissions
credits. CER has deployed its systems throughout China and in such
international markets as Egypt, Korea, Vietnam and Malaysia. CER
focuses on numerous industries in which a rapid payback on
invested capital is achieved by its customers, including:
chemical, paper manufacturing, refining (including methanol
refining), etc. CER continues to invest in R&D and plans to build
China's first state-of-the-art energy recovery system research and
fabrication facility to allow it to meet the increased demand for
its products and services. For more information on CER, please
visit:
|
|
http://www.chinaenergyrecovery.com/s/Home.asp.
|
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
China Information Security Technology, Inc.
|
|
|
Ticker Symbol & Exchange:
|
|
Nasdaq: CPBY
|
|
|
Investor Relations Contact:
|
|
Iris Yan
|
|
|
Investor Relations Contact Phone:
|
|
86-755-83704767
|
|
|
Web:
|
|
www.chinacpby.com
|
|
|
Date of Presentation:
|
|
09/10/09
|
|
|
|
|
|
|
|
China Information Security Technology, Inc. headquartered in
Shenzhen, China, is a leading application software developer,
systems integrator and full-service Geographic Information Systems
("GIS" ) solutions provider to the public security and civil-use
markets in China, aiming to use information technology to improve
public safety and information management. Its main business lines
range from digital information security, to GIS solutions, and
digital hospital information systems. The Company provides a broad
portfolio of fully integrated solutions and services, including its
First Responder Coordination Platform, Intelligent Border Control
System, Residence Card Information Management System, Digital
Hospital Information System and Police- and Civil-use GIS products,
to serve the growing demand for digital hospital and electronic
medical record systems in China. Its commitment to leading-edge
technology and quality assurance has won the Company numerous
government and enterprise contracts throughout China.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
China North East Petroleum Holdings Ltd.
|
|
|
Ticker Symbol & Exchange:
|
|
NYSE Amex: NEP
|
|
|
Investor Relations Contact:
|
|
Chao Jiang
|
|
|
Investor Relations Contact Phone:
|
|
212-307-3568
|
|
|
Web:
|
|
www.cnepetroleum.com
|
|
|
Date of Presentation:
|
|
09/09/09
|
|
|
|
|
|
|
|
China North East Petroleum Holdings Limited is an independent oil
company that engages in oil drilling project management and the
production of crude oil in proven oilfields in Northern China. The
Company is a pioneer in China's private oil exploration and
production industry, and the first Chinese non-state-owned oil
company trading on the NYSE Amex.
|
|
|
|
The Company has a lease and sales contract with the PetroChina to
sell its produced crude oil for use in the China marketplace. The
Company currently operates four oilfields in Northern China. For
more information about the Company, please visit
http://www.cnepetroleum.com
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
China Sky One Medical, Inc.
|
|
|
Ticker Symbol & Exchange:
|
|
NASDAQ: CSKI
|
|
|
Investor Relations Contact:
|
|
Mr. Stanley Hao
|
|
|
Investor Relations Contact Phone:
|
|
86-451-53994069
|
|
|
Web:
|
|
www.cski.com.cn
|
|
|
Date of Presentation:
|
|
September 10th, 2009
|
|
|
|
|
|
|
|
China Sky One Medical, Inc. manufactures, markets and distributes
branded pharmaceutical products mainly for external use, including
Chinese medicines, western medicines, diagnostic kits and cosmetics.
Its "Kang Xi" and "Yu Fu" trademarks are well known for high quality
and value in China. The Company's distribution network covers
approximately 5500 retail stores and hospitals in 24 provinces of
China and 20 other countries and regions. Its leading products
include its Sumei Slim Patch for weight loss, its Anti-hypertension
Patch, its Compound Camphor Cream for treating dermatitis, and other
various drops and ointments.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
China Technology Development Group Corp.
|
|
|
Ticker Symbol & Exchange:
|
|
CTDC
|
|
|
Investor Relations Contact:
|
|
selina.xing@chinactdc.com
|
|
|
Investor Relations Contact Phone:
|
|
852-3112 8461, +86-2669 8709
|
|
|
Web:
|
|
www.chinactdc.com
|
|
|
Date of Presentation:
|
|
September 10th 2009
|
|
|
|
|
|
|
|
China Technology Development Group Corporation (NASDAQ:CTDC) ("the
Company" or "CTDC" ) is an integrated green energy group, focusing on
the provision of solar energy products and solutions in China.
|
|
|
|
The Company's major shareholders include China Merchants Group, one
of the biggest state-owned conglomerates in China, and Beijing
Holdings Limited, the largest integrated conglomerate owned and
operated by Beijing Municipal Government outside Mainland China.
|
|
|
|
CTDC is expanding its business through merger and acquisition in
Chinese new energy industry, and committed to building a greener
world by bringing clean and affordable energy to every family in
China.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
China TransInfo Technology Corporation
|
|
|
Ticker Symbol & Exchange:
|
|
CTFO Nasdaq GM
|
|
|
Investor Relations Contact:
|
|
Fan Zhou
|
|
|
Investor Relations Contact Phone:
|
|
86 10 8267 1299 - 8033
|
|
|
Web:
|
|
www.chinatransinfo.com
|
|
|
Date of Presentation:
|
|
September 10th 9:10am ET
|
|
|
|
|
|
|
|
China TransInfo is primarily focused on providing transportation
information services and comprehensive solutions based on GIS
technologies. The Company aims to become the largest transportation
information products and comprehensive solutions provider, as well
as the largest real time transportation information platform
operator and provider in China. The Company owns software copyrights
for 75 software products and has won 5 of the 10 model cases
sponsored by the PRC Ministry of Communications. The Company's
affiliation with Peking University provides the Company access to
the University's GeoGIS Research Laboratory, including 30 Ph.D.
researchers. As a result, the Company is playing a key role in
setting the standards for electronic transportation information
solutions.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
China Wind Systems, Inc.
|
|
|
Ticker Symbol & Exchange:
|
|
CWSI OTC BB
|
|
|
Investor Relations Contact:
|
|
Crocker Coulson
|
|
|
Investor Relations Contact Phone:
|
|
646-213-1915
|
|
|
Web:
|
|
www.chinawindsystems.com
|
|
|
Date of Presentation:
|
|
September 11, 2009 10:25 a.m. ET
|
|
|
|
|
|
|
|
China Wind Systems supplies forged rolled rings to the wind power
and other industries and industrial equipment to the textile and
energy industries in China. With its newly finished state-of-the-art
production facility, the Company is expected soon to significantly
increase its shipment of high-precision rolled rings and other
essential components primarily to the wind power and other
industries.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
China XD Plastics Company Ltd.
|
|
|
Ticker Symbol & Exchange:
|
|
CXDC.OB
|
|
|
Investor Relations Contact:
|
|
Crocker Coulson
|
|
|
Investor Relations Contact Phone:
|
|
646 213 1915
|
|
|
Web:
|
|
http://www.chinaxd.net/
|
|
|
Date of Presentation:
|
|
09/10/09
|
|
|
|
|
|
|
|
China XD Plastics Company Ltd., through its wholly owned subsidiary
Harbin Xinda Macromolecule Material ("Xinda" ), develops,
manufactures, and distributes modified plastics, primarily for
automotive applications. The Company's specialized plastics are used
in the exterior and interior trim and in the functional components
of more than 30 automobile brands manufactured in China, including
Audi, Red Flag, Volkswagen, and Mazda. China XD currently has the
largest production base of modified plastics for automotive
applications in China. It now has 396 full-time employees and is
headquartered in Harbin, Heilongjiang Province, in Northeast China.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
CHINA YOUTH MEDIA, INC.
|
|
|
Ticker Symbol & Exchange:
|
|
OTC BB: CHYU
|
|
|
Investor Relations Contact:
|
|
Sophia Kim; American Capital Ventures
|
|
|
Investor Relations Contact Phone:
|
|
(310) 728-1457;(305) 918-7000
|
|
|
Web:
|
|
www.ChinaYouthMedia.com
|
|
|
Date of Presentation:
|
|
September 9, 2009 9:35AM-10:00AM
|
|
|
|
|
|
|
|
China Youth Media, Inc., a youth marketing and media company,
delivers advertising and content in the People's Republic of China.
The company provides advertisers and corporations with direct and
centralized access to China's highly valuable student population,
which constitutes a key segment of the world's largest youth market.
China Youth Media has secured an exclusive 30-year contract with the
Chinese government controlled corporation, China Youth Interactive,
which grants the company a broad range of rights to market to
China's 30 million plus college students with preferred access
online, on campus and via mobile. The company offers this
unprecedented access through a campus media network consisting of an
Intranet Television Network and media portal called Koobee,
sponsored campus events and advanced mobile marketing.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
ChinaNet Online Holdings, Inc.
|
|
|
Ticker Symbol & Exchange:
|
|
CHNT OTCBB
|
|
|
Investor Relations Contact:
|
|
HC International, Inc.
|
|
|
Investor Relations Contact Phone:
|
|
Ted Haberfield, 760-755-2716
|
|
|
Web:
|
|
www.chinanet-online.com
|
|
|
|
|
|
|
|
ChinaNet Online Holdings, Inc. (OTCBB:CHNT), through its wholly
owned subsidiary, China Net Online Media Group Limited (the "China
Net" ), a leading full-service media development, advertising and
communications company for small and medium companies (SME's) in
China. Founded in 2003 and based in Beijing, PRC, the Company
provides internet advertising and other services for Chinese SME's
via its well recognized portal website 28.com, TV commercials and
program production via the China-Net TV, and in-house LCD
advertising on banking kiosks targeting Chinese banking patrons.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
Cipher Pharmaceuticals Inc.
|
|
|
Ticker Symbol & Exchange:
|
|
DND
|
|
|
Investor Relations Contact:
|
|
Craig Armitage
|
|
|
Investor Relations Contact Phone:
|
|
416-815-0700 x 278
|
|
|
Web:
|
|
www.cipherpharma.com
|
|
|
Date of Presentation:
|
|
09/11/09
|
|
|
|
|
|
|
|
Cipher is a drug development company focused on commercializing
novel formulations of successful, currently marketed molecules using
advanced drug delivery technologies. Cipher's strategy is to
in-license products that incorporate proven drug delivery
technologies and advance them through the clinical development and
regulatory approval stages, after which the products are
out-licensed to international partners. The Company's lead compound,
CIP-FENOFIBRATE, received final approval from the U.S. FDA and
Health Canada in 2006. The product is being marketed in the United
States by Kowa Pharmaceuticals America under the label Lipofen(R).
In addition, Cipher is developing formulations of the pain reliever
tramadol (tentative FDA approval in February 2009) and the acne
treatment isotretinoin (FDA approvable letter in April 2007).
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
City Telecom
|
|
|
Ticker Symbol & Exchange:
|
|
CTEL NASDAQ
|
|
|
Investor Relations Contact:
|
|
John Marco
|
|
|
Investor Relations Contact Phone:
|
|
310-819-2948
|
|
|
Web:
|
|
http://www.ctigroup.com.hk/en/about.html
|
|
|
Date of Presentation:
|
|
Sept 10th 2009
|
|
|
|
|
|
|
|
City Telecom has built the most extensive and fastest, end-to-end
fiber network in Hong Kong. The Company has established solid market
position as the second largest and fastest growing broadband service
provider in the country. It is aggressively expanding its market
penetration, taking market share away from competitors, in an effort
to become the largest IP service provider in Hong Kong's $3.6B
market by 2016. Moreover, with its high speed FTTH network, low
churn rate and commitment to customer service, City Telecom has been
able to increase its average revenue per user and margins.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
Clarient, Inc.
|
|
|
Ticker Symbol & Exchange:
|
|
NASDAQ: CLRT
|
|
|
Investor Relations Contact:
|
|
Matt Clawson
|
|
|
Investor Relations Contact Phone:
|
|
9494/474-4300
|
|
|
Web:
|
|
www.clarientinc.com
|
|
|
Date of Presentation:
|
|
09/09/09
|
|
|
|
|
|
|
|
Clarient combines innovative diagnostic technologies with
world-class pathology expertise to assess and characterize cancer.
Clarient aims to become the leader in cancer diagnostics by
translating cancer discovery into improved patient care. Clarient's
principal customers include pathologists, oncologists, hospitals and
biopharmaceutical companies. Clarient is a centralized resource for
leading diagnostic technologies, having created a state-of-the-art
commercial cancer laboratory providing the most advanced diagnostic
services available onsite and over the web. Resulting diagnostic
reports and analyses are made available to customers through
Clarient's Internet-based portal, PATHSiTE. Clarient also plans to
develop and market new, proprietary "companion" diagnostic markers
for numerous cancers.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
CNS Response, Inc.
|
|
|
Ticker Symbol & Exchange:
|
|
CNSO
|
|
|
Investor Relations Contact:
|
|
Marty Tullio
|
|
|
Investor Relations Contact Phone:
|
|
949-553-9748
|
|
|
Web:
|
|
www.cnsresponse.com
|
|
|
Date of Presentation:
|
|
09/09/09
|
|
|
|
|
|
|
|
Today physicians base treatments on objective test data provided by
blood tests, MRIs or X-Rays. Even though CNS drugs represent the
largest drug class, similar objective data have not been available
to physicians prescribing them -until now!
|
|
|
|
CNSO is a life-sciences data company with a new prescription to
personalize medication management: a patented biomarker system
comparing individual patient EEGs with a reference outcome database.
The result: a 2-page report that provides physicians guidance with
individualized medication options for his patient. We call it
referenced-EEG (rEEG), and it's shown extraordinary results in
eleven clinical trials and case series.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
CO2 Solution Inc.
|
|
|
Ticker Symbol & Exchange:
|
|
TSX Venture: CST
|
|
|
Investor Relations Contact:
|
|
Glenn Kelly
|
|
|
Investor Relations Contact Phone:
|
|
418-842-3456, ext. 205
|
|
|
Web:
|
|
www.co2solution.com
|
|
|
Date of Presentation:
|
|
September 9, 2009 at 10:00AM
|
|
|
|
|
|
|
|
CO2 Solution Inc. has developed a proprietary bio-technological
platform for the efficient capture of carbon dioxide (CO2), the most
important greenhouse gas (GHG), from coal fired power plants and
other emitters. The Company's technology platform exploits a
bio-catalyst (enzyme), carbonic anhydrase, which functions within
humans and other mammals to manage CO2 during respiration. CO2
Solution has adapted the enzyme to function within an industrial
environment, and thus has taken advantage of a biomimetic approach
to CO2 capture based on millions of years of evolution. The Company
is commercializing its technology for coal fired power generation,
the oil sands and other CO2-intensive industries where a low-cost
capture solution is key to meeting climate change legislation in a
cost effective manner.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
Coastal Contacts Inc
|
|
|
Ticker Symbol & Exchange:
|
|
COA: TSX
|
|
|
Investor Relations Contact:
|
|
Terry Vanderkruyk
|
|
|
Investor Relations Contact Phone:
|
|
604-676-4498
|
|
|
Web:
|
|
www.coastalcontacts.com
|
|
|
Date of Presentation:
|
|
Wednesday, September 9th 5:20pm
|
|
|
|
|
|
|
|
Coastal Contacts is the world's largest online vision care supplier.
Providing contact lenses, eyeglasses and other complimentary vision
care products to consumers worldwide, Coastal Contacts is proud to
provide an affordable, convenient option for high quality vision
care products. With its world class operations in North America,
Europe and Asia, Coastal Contacts offers a unique blend of private
label and branded products to over 150 countries across the globe.
Already #1 in many of its markets, Coastal is rapidly advancing
toward its goal of becoming the "World's Optical Store."
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
Columbia Laboratories, Inc.
|
|
|
Ticker Symbol & Exchange:
|
|
Nasdaq: CBRX
|
|
|
Investor Relations Contact:
|
|
Melody Carey
|
|
|
Investor Relations Contact Phone:
|
|
917-322-2571
|
|
|
Web:
|
|
www.columbialabs.com
|
|
|
Date of Presentation:
|
|
09/10/09
|
|
|
|
|
|
|
|
Columbia Laboratories, Inc. is a specialty pharmaceutical company
focused on developing and commercializing products for the women's
healthcare and endocrinology markets that use its novel bioadhesive
drug delivery technology. Columbia's U.S. sales organization markets
CRINONE 8% (progesterone gel) in the United States for progesterone
supplementation as part of an Assisted Reproductive Technology
treatment for infertile women with progesterone deficiency and
STRIANT (testosterone buccal system) for the treatment of
hypogonadism in men. The Company's partners market CRINONE 8%,
STRIANT and three other products to additional U.S. and foreign
markets.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
Copper Mountian Mining Corporation
|
|
|
Ticker Symbol & Exchange:
|
|
CUM (TSX)
|
|
|
Investor Relations Contact:
|
|
Don Graham
|
|
|
Investor Relations Contact Phone:
|
|
604.682.2992 ext: 225, Don@CuMtn.com
|
|
|
Web:
|
|
www.CuMtn.com
|
|
|
Date of Presentation:
|
|
September 9th, 4:05pm
|
|
|
|
|
|
|
|
Copper Mountain Mining (TSX:CUM) has partnered with Mitsubishi
Materials Corporation to bring back into production the Copper
Mountain Project, by mid-2011. The Project is owned 75% by Copper
Mountain Mining Corporation and 25% by Mitsubishi Materials
Corporation.
|
|
|
|
The Company completed an independent feasibility study that
confirmed the economic viability of bringing back into production a
conventional open pit mine with a 35,000 tonnes per day mill. The
mine, with a resource of 5 billion pounds of Copper, is designed to
produce approximately 100 million pounds of copper per year in a
copper concentrate with gold and silver credits.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
Cortex Pharmaceuticals, Inc.
|
|
|
Ticker Symbol & Exchange:
|
|
COR
|
|
|
Investor Relations Contact:
|
|
Dian Griesel, IRG, New York
|
|
|
Investor Relations Contact Phone:
|
|
212-825-3210
|
|
|
Web:
|
|
www.cortexpharm.com
|
|
|
Date of Presentation:
|
|
Thursday, September 10, 2009
|
|
|
|
|
|
|
|
Cortex Pharmaceuticals, Inc. is a neuroscience company focused on
the development of AMPAKINE compounds, a technology that acts on
the AMPA receptor system of neurons in the brain to up-regulate
signaling between brain cells. The compounds are small, orally
active molecules, which can be used to treat ADHD, Alzheimer's,
Huntington's, Fragile X and Rett's syndromes and also depression and
schizophrenia. Cortex has two lead compounds, CX1739, currently
being evaluated in a Phase II study of sleep apnea and CX717 which
has shown positive results in the treatment of drug induced
respiratory depression and in ADHD in adult patients.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
Cyber Digital, Inc.
|
|
|
Ticker Symbol & Exchange:
|
|
CYBD (OTC)
|
|
|
Investor Relations Contact:
|
|
J.C. Chatpar
|
|
|
Investor Relations Contact Phone:
|
|
631-231-1200
|
|
|
Web:
|
|
www.cyberdigitalinc.com
|
|
|
Date of Presentation:
|
|
09/11/09
|
|
|
|
|
|
|
|
Cyber Digital designs and develops a vast array of software based
digital switching systems and Internet Protocol (IP) broadband
infrastructure systems for network operators worldwide. Cyber
Digital's mission is to become a major network operator offering
managed broadband, VoIP and VPN services in unserved and underserved
areas in the U.S. by deploying its systems with the support of
federal government grants funded by the American Recovery and
Reinvestment Act of 2009. While stimulating economies in these
areas, it generates recurring revenues from selling its services to
small businesses, residential customers and anchor institutions such
as hospitals, schools and public safety facilities.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
CyberDefender Corporation
|
|
|
Ticker Symbol & Exchange:
|
|
OTCBB:CYDE
|
|
|
Investor Relations Contact:
|
|
Kevin Harris
|
|
|
Investor Relations Contact Phone:
|
|
213-689-8631 x127
|
|
|
Web:
|
|
www.cyberdefender.com
|
|
|
Date of Presentation:
|
|
09/11/09
|
|
|
|
|
|
|
|
CyberDefender Corporation (OTCBB:CYDE), is a rapidly growing
provider of cyber-security software and services to consumers.
CyberDefender antispyware, antivirus and identity protection
products are based on its patent-pending peer to peer earlyNETWORK
technology. In addition, CyberDefender markets PC optimization
software and Live Help Desk services. Through its multi-channel
marketing approach utilizing web, search, direct response tv and
radio advertising and retail distribution --CyberDefender is on
track to reach over one million subscribers by 2010. To date, more
than 15 million consumers have used CyberDefender products and
services. For additional information: www.cyberdefender.com.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
Cyclacel Pharmaceuticals, Inc.
|
|
|
Ticker Symbol & Exchange:
|
|
CYCC
|
|
|
Investor Relations Contact:
|
|
Corey Sohmer
|
|
|
Investor Relations Contact Phone:
|
|
908-517-7330
|
|
|
Web:
|
|
www.cyclacel.com
|
|
|
Date of Presentation:
|
|
09/10/09
|
|
|
|
|
|
|
|
Cyclacel is a biopharmaceutical company dedicated to the discovery,
development and commercialization of novel, mechanism-targeted drugs
to treat human cancers and other serious disorders. Sapacitabine, a
cell cycle modulating nucleoside analog, is in Phase 2 studies for
the treatment of elderly AML, MDS, NSCLC and in Phase 1 in
combination with seliciclib. Seliciclib, a CDK inhibitor, is in
Phase 2 for the treatment of lung and nasopharyngeal cancers.
CYC116, an Aurora kinase and VEGFR2 inhibitor, is in Phase 1 in
patients with solid tumors. ALIGN markets in the U.S. Xclair Cream
for radiation dermatitis, Numoisyn Liquid and Lozenges for
xerostomia.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
Cytori Therapeutics, Inc.
|
|
|
Ticker Symbol & Exchange:
|
|
NASDAQ: CYTX
|
|
|
Investor Relations Contact:
|
|
Tom Baker
|
|
|
Investor Relations Contact Phone:
|
|
858.875.5258
|
|
|
Web:
|
|
www.cytoritx.com
|
|
|
Date of Presentation:
|
|
September 20, 2009, 10:50-11:15 AM
|
|
|
|
|
|
|
|
Cytori is committed to providing patients and physicians around the
world with medical technologies, which harness the potential of
adult stem and regenerative cells from adipose tissue. With the
introduction of a family of medical devices, we have made a
patient's own clinical grade stem and regenerative cells available
to them at the point-of-care.
|
|
|
|
The Celution System family of medical devices and instruments is
being sold into the European and Asian cosmetic and reconstructive
surgery markets, while we seek regulatory clearance in the United
States. Our StemSource product line is sold globally for cell
banking and research applications.
|
|
|
|
Our product development pipeline spans cardiovascular disease, renal
failure, pelvic health among other acute and chronic conditions.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
CytRx Corporation
|
|
|
Ticker Symbol & Exchange:
|
|
NASDAQ: CYTR
|
|
|
Investor Relations Contact:
|
|
Thomas Wagner
|
|
|
Investor Relations Contact Phone:
|
|
800-385-5790 x152, 718-233-2600 x152
|
|
|
Web:
|
|
www.cytrx.com
|
|
|
Date of Presentation:
|
|
September 9, 2009 at 2:25 p.m. ET
|
|
|
|
|
|
|
|
CytRx Corporation is a biopharmaceutical research and development
company engaged in the development of high-value human therapeutics.
The CytRx drug development pipeline includes programs in clinical
development for cancer indications, including tamibarotene in a
registration study for the treatment of acute promyelocytic leukemia
(APL). In addition, CytRx is developing two drug candidates based on
its industry-leading molecular chaperone technology, which aims to
repair or degrade misfolded proteins associated with disease. CytRx
also maintains a 39% equity interest in publicly traded RXi
Pharmaceuticals, Inc. (NASDAQ: RXII).
|
|
|
|
A webcast of the CytRx presentation will be posted to the Company's
Web site at www.cytrx.com.
|
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
Delcath Systems, Inc.
|
|
|
Ticker Symbol & Exchange:
|
|
DCTH
|
|
|
Investor Relations Contact:
|
|
EVC Group
|
|
|
Investor Relations Contact Phone:
|
|
EVC Group, Doug Sherk, 415-896-6491
|
|
|
Web:
|
|
www.delcath.com
|
|
|
Date of Presentation:
|
|
Friday, Sept. 11th
|
|
|
|
|
|
|
|
Delcath Systems (Nasdaq:DCTH) is at the forefront of the regional
treatment of cancer with a promising therapy to shrink tumors in
the liver. Delcath's Percutaneous Hepatic Perfusion (PHP )
technology allows physicians to deliver significantly higher doses
of anti-cancer drugs to the liver without exposing the patient's
entire body to those same potent levels of drug. PHP is an
investigational treatment currently undergoing testing in Phase
III and Phase II clinical trials.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
Depomed, Inc.
|
|
|
Ticker Symbol & Exchange:
|
|
DEPO NASDAQ
|
|
|
Investor Relations Contact:
|
|
DeDe Sheel, FD
|
|
|
Investor Relations Contact Phone:
|
|
415 293 4412
|
|
|
Web:
|
|
www.depomed.com
|
|
|
Date of Presentation:
|
|
09/09/09
|
|
|
|
|
|
|
|
Depomed is an innovative specialty pharmaceutical company focused on
improving the efficacy, safety, and patient compliance of compounds
across key therapeutic categories with a long term focus on woman's
health. Since its founding in August 1995, the company has advanced
two products to market and has developed a pipeline with late-stage
product opportunities intended to address common medical conditions
affecting large patient populations. The company utilizes its
proven, proprietary AcuForm(TM) drug delivery technology to improve
existing oral medications, allowing for extended, controlled release
of medications to the upper gastrointestinal tract.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
East Asia Minerals Corporation
|
|
|
Ticker Symbol & Exchange:
|
|
EAS: TSXV
|
|
|
Investor Relations Contact:
|
|
Nick Kohlmann
|
|
|
Investor Relations Contact Phone:
|
|
(416) 792-8734
|
|
|
Web:
|
|
www.EAminerals.com
|
|
|
Date of Presentation:
|
|
Thursday, September 10, 2009
|
|
|
|
|
|
|
|
East Asia Minerals (EAS-TSXV) is an Asian-based, Canadian mineral
exploration company with gold and copper exploration properties in
Indonesia, and uranium exploration properties in Mongolia. In
Indonesia the Company has a 70 to 85% interest in six advanced gold
and gold-copper properties located in Aceh Province, Sumatra, and
Sangihe Island, North Sulawesi. Two of these, the Sangihe
(Binebase-Bawone) and Barisan 1 (Abong) gold projects, are being
advanced to define NI43-101 compliant resources. The Company owns
eleven uranium properties, including the advanced Ingiin-Nars, Ulaan
Nuur and Enger uranium projects and four phosphate properties in
Mongolia. East Asia currently has 65,365,372 shares outstanding.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
eMagin Corporation
|
|
|
Ticker Symbol & Exchange:
|
|
EMAN
|
|
|
Investor Relations Contact:
|
|
Paul Campbell, CFO & Treasurer
|
|
|
Investor Relations Contact Phone:
|
|
425-749-3600
|
|
|
Web:
|
|
www.emagin.com
|
|
|
Date of Presentation:
|
|
09/09/09
|
|
|
|
|
|
|
|
eMagin Corporation is a leader in OLED (organic light emitting
diode) technology. We design, develop, manufacture, and market OLED
on silicon microdisplays, virtual imaging products which utilize
OLED microdisplays, and related products. Our virtual imaging
products integrate OLED, technology with silicon chips to produce
high-resolution microdisplays smaller than one-inch diagonally
which, when viewed through a magnifier, create virtual images that
appear comparable in size to that of a computer monitor or a
large-screen television. Our products enable our original equipment
manufacturer ("OEM" ) customers to develop and market improved or new
electronic products.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
EMRISE CORPORATION
|
|
|
Ticker Symbol & Exchange:
|
|
NYSE ARCA: ERI
|
|
|
Investor Relations Contact:
|
|
Rene Caron
|
|
|
Investor Relations Contact Phone:
|
|
9494/474-4300
|
|
|
Web:
|
|
www.emrise.com
|
|
|
Date of Presentation:
|
|
09/11/09
|
|
|
|
|
|
|
|
EMRISE designs, manufactures and markets electronic devices,
sub-systems and equipment for aerospace, defense, industrial and
communications markets. Its products perform power supply and power
conversion; radio frequency (RF) and microwave signal processing;
and network access and timing and synchronization of communications
networks. Primary growth drivers include using its RF devices in
radio-controlled improvised explosive device jamming systems, and
its Network Timing and Synchronization products in edge networks.
EMRISE serves customers in North America, Europe and Asia, including
most of the Fortune 100 in the U.S. doing business in EMRISE's
markets and similar-size companies in Europe and Asia, through its
operations in the U.S., England and France.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
Emisphere Technologies, Inc.
|
|
|
Ticker Symbol & Exchange:
|
|
OTC BB: EMIS
|
|
|
Investor Relations Contact:
|
|
Michael Garone
|
|
|
Investor Relations Contact Phone:
|
|
(973) 532-8005
|
|
|
Web:
|
|
http://www.emisphere.com
|
|
|
Date of Presentation:
|
|
09/09/09
|
|
|
|
|
|
|
|
Emisphere is a biopharmaceutical company that focuses on a unique
and improved delivery of therapeutic molecules or nutritional
supplements using its Eligen Technology. These molecules and
compounds could be currently available or in development. Such
molecules are usually delivered by injection; in many cases, their
benefits are limited due to poor bioavailability, slow on-set of
action or variable absorption. The Eligen Technology can be applied
to oral formulations as well as other delivery pathways, such as
buccal, rectal, inhalation, intra-vaginal or transdermal.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
Evans Bancorp, Inc.
|
|
|
Ticker Symbol & Exchange:
|
|
EVBN: Nasdaq
|
|
|
Investor Relations Contact:
|
|
Deborah Pawlowski
|
|
|
Investor Relations Contact Phone:
|
|
716-843-3809
|
|
|
Web:
|
|
www.evansbancorp.com
|
|
|
Date of Presentation:
|
|
09.11.2009
|
|
|
|
|
|
|
|
Evans Bancorp, Inc. is a financial holding company and the parent
company of Evans Bank, N.A., a commercial bank with $553 million in
assets and $451 million in deposits at June 30, 2009. The bank has
13 branches located in Western New York. Evans National Leasing,
Inc., an indirect wholly-owned subsidiary of Evans Bank is a general
business equipment leasing company with customers throughout the
U.S. Evans Bancorp's wholly-owned insurance subsidiary, The Evans
Agency, provides retail property and casualty insurance through 15
insurance offices in the Western New York region. Evans Investment
Services, a wholly-owned subsidiary of Evans Bank, provides
non-deposit investment products such as annuities and mutual funds.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
Exco Resources Ltd ("Exco" )
|
|
|
Ticker Symbol & Exchange:
|
|
EXS (ASX) - Listed 1998
|
|
|
Investor Relations Contact:
|
|
Mr Michael Anderson (Managing Director)
|
|
|
Investor Relations Contact Phone:
|
|
61 (0)412 496 797
|
|
|
Web:
|
|
www.excoresources.com.au
|
|
|
Date of Presentation:
|
|
10th of September 2009, 4.30pm - 4.55pm, Homes II Salon (4th Floor,
New York Palace Hotel)
|
|
|
|
|
|
Exco is focused on developing its portfolio of Australian-based
copper and gold projects.
|
|
|
|
|
|
In NW Queensland Exco holds a ~4,100km2 land package, in the highly
prospective Mt Isa Block. Feasibility studies are underway on the
Cloncurry Copper Project, whilst the Hazel Creek Project offers
substantial exploration upside. To date Exco has established a
resource base of 57Mt containing 495,000t of copper and 480,000oz of
gold.
|
|
|
|
In South Australia Exco is developing the White Dam Project.
Approvals and funding arrangements are in place for an operation
that will produce ~120,000oz of gold over a 2 ½ year period. Site
works are underway with first production targeted in Q1/2010.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
Exeter Resource Corporation
|
|
|
Ticker Symbol & Exchange:
|
|
NYSE-AMEX: XRA
|
|
|
Investor Relations Contact:
|
|
Rob Grey
|
|
|
Investor Relations Contact Phone:
|
|
888 688 9592
|
|
|
Web:
|
|
www.exeterresource.com
|
|
|
Date of Presentation:
|
|
09/10/09
|
|
|
|
|
|
|
|
Exeter Resource Corporation is one of the most active exploration
and mine development companies operating in South America. The
Company has C$30 million in cash, no debt and two principal assets.
The Caspiche gold-copper porphyry discovery and the Cerro Moro
high-grade gold-silver deposit.
|
|
|
|
Caspiche's initial NI43-101 compliant inferred mineral resource
estimate totals 8.7 million ounces gold and 2.1 billion pounds of
copper*.A second mineral resource estimateis expected to be
available in September 2009.
|
|
|
|
Cerro Moro's initial NI43-101 compliant inferred resource estimate
totals 646,000 ounces gold equivalent**, at a grade of 18 grams per
tonne gold equivalent** (0.52 ounces per ton).
|
|
|
|
The focus will be on advancing the Escondida vein which contains
518,000 ounces gold equivalent** at a grade of 34 g/t gold
equivalent** (0.99 ounces per ton)
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
First Ship Lease Trust
|
|
|
Ticker Symbol & Exchange:
|
|
D8DU, SGX-ST
|
|
|
Investor Relations Contact:
|
|
Fung-Leng, Chen (Mr)
|
|
|
Investor Relations Contact Phone:
|
|
FLChen@firstshiplease.com, 65 96853910
|
|
|
Web:
|
|
www.FSLTrust.com
|
|
|
Date of Presentation:
|
|
09/10/09
|
|
|
|
|
|
|
|
First Ship Lease Trust ("FSL Trust" ) (SGX: D8DU, OTCQX-ADR: FSHPY)
owns a portfolio of 23 vessels which are leased to maritime
companies on long-term bareboat charters. The portfolio is
broadly-diversified across five shipping sub-sectors and eight
lessees. The portfolio has an average remaining lease of eight years
and contracted revenue of about US$800 million as at 30 June 2009.
|
|
|
|
|
|
|
FSL Trust is managed by FSL Trust Management Pte Ltd, the
Trustee-Manager. The Trustee-Manger is focused on growing and
diversifying FSL Trust's portfolio through cash flow accretive
acquisitions with long-term bareboat charters that support regular
and stable distributions to its unitholders.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
FX Energy, Inc.
|
|
|
Ticker Symbol & Exchange:
|
|
fxen: Nasdaq
|
|
|
Investor Relations Contact:
|
|
Scott J. Duncan
|
|
|
Investor Relations Contact Phone:
|
|
801 486-5555
|
|
|
Web:
|
|
www.fxenergy.com
|
|
|
Date of Presentation:
|
|
09/09/09
|
|
|
|
|
|
|
|
FX Energy is an independent gas and oil exploration and production
company with its principal production, reserves, and exploration
activities in Poland. Relatively little gas has been discovered in
Poland's sector of the North European Permian Basin compared to the
UK, Dutch and German sectors. Consequently, management believes the
Polish Permian Basin is under explored and under exploited and
offers high potential for discovering significant amounts of
hydrocarbons. Based on this thesis, FX Energy has acquired 4.9
million net acres in Poland, generated a number of attractive
prospects, drilled several successful wells and established reserves
and cashflow for its shareholders.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
Gadot Chemical Tankers & Terminals Ltd.
|
|
|
Investor Relations Contact:
|
|
Amit Magen
|
|
|
Investor Relations Contact Phone:
|
|
972-9-890-9500
|
|
|
Web:
|
|
www.gadot.com
|
|
|
Date of Presentation:
|
|
09/10/09
|
|
|
|
|
|
|
|
Gadot is Israel's leading chemical supply chain & distribution
corporation. Through its subsidiaries, Gadot ships, stores, and
distributes liquid chemicals, specialty chemicals, oils and related
materials worldwide. Founded in 1958 as a chemical importer, Gadot
expanded to offer its clients a full range of services, delivering
value to customers across the chemical value chain, from acquiring
customer-specific chemicals, logistical handling including shipping
and transport, offloading, storage and delivery. Gadot's operations
include the import, marketing and sales of chemicals and other raw
materials in Israel and Europe. The company is currently expanding
its chemical supply chain operations globally, with emphasis on
green chemistry.
|
|
|
|
Gadot is a fully owned subsidiary of Ampal which is dual-listed on
NADAQ and Tel Aviv exchange.
|
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
General Steel Holdings, Inc.
|
|
|
Ticker Symbol & Exchange:
|
|
NYSE: GSI
|
|
|
Investor Relations Contact:
|
|
Jessica Barist Cohen
|
|
|
Investor Relations Contact Phone:
|
|
Ogilvy Financial, New York 646-460-9989
|
|
|
Web:
|
|
www.gshi-steel.com
|
|
|
Date of Presentation:
|
|
09/10/09
|
|
|
|
|
|
|
|
General Steel Holdings, Inc., (NYSE: GSI), headquartered in Beijing,
China, operates a diverse portfolio of Chinese steel companies. With
6.3 million metric tons aggregate production capacity, its companies
serve various industries and produce a variety of steel products
including rebar, hot-rolled carbon and silicon sheet, high-speed
wire and spiral-weld pipe. General Steel Holdings, Inc. has steel
operations in Shaanxi and Guangdong provinces, Inner Mongolia
Autonomous Region and Tianjin municipality. For more information,
please visit www.gshi-steel.com.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
Genetix Group plc
|
|
|
Ticker Symbol & Exchange:
|
|
GTX.L
|
|
|
Investor Relations Contact:
|
|
Jonathan Birt, Fin Dynamics
|
|
|
Investor Relations Contact Phone:
|
|
44 20 7269 7205
|
|
|
Web:
|
|
www.genetix.com
|
|
|
Date of Presentation:
|
|
9th August, 4.30pm
|
|
|
|
|
|
|
|
Genetix is a leading provider of solutions for imaging and
intelligent image analysis in the life science and clinical markets.
The Gourp's systems are used in mainstream research, in the
development of pharmaceuticals and biotherapeutics, and in clinical
diagnostics. In April 2009 they acquired SlidePath Ltd, a company
developing and deploying web-enabled, enterprise-level solutions
that support the growing demand for global, high throughput image
and data handling in the digital pathology market.
|
|
|
|
Genetix is headquartered in New Milton, United Kingdom with direct
sales in USA, major European markets and Japan, together with a wide
distributor network.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
Genta Incorporated
|
|
|
Ticker Symbol & Exchange:
|
|
GETA
|
|
|
Investor Relations Contact Phone:
|
|
Info@genta.com, 908-286-3980
|
|
|
Web:
|
|
www.genta.com
|
|
|
Date of Presentation:
|
|
09/09/09
|
|
|
|
|
|
|
|
Genta is a biopharmaceutical company focused on delivering
innovative products for the treatment of patients with cancer. Two
major programs anchor our research platform: DNA/RNA Medicines and
Small Molecules. Genasense (oblimersen sodium) Injection is the
lead compound of our DNA/RNA Medicines program. Genta has
completed its Phase 3 trial of Genasense in advanced melanoma and
will present results in the 4th quarter 2009. Our Small Molecule
program is focused on tesetaxel, an orally absorbed taxane in
Phase 2 clinical trials, and gallium products including Ganite
(gallium nitrate injection), which Genta markets exclusively in
the U.S., and oral gallium-containing compounds that target
patients with accelerated bone loss.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
GeoResources, Inc.
|
|
|
Ticker Symbol & Exchange:
|
|
GEOI
|
|
|
Investor Relations Contact:
|
|
Cathy Kruse
|
|
|
Investor Relations Contact Phone:
|
|
701-572-2020 x113
|
|
|
Web:
|
|
www.georesourcesinc.com
|
|
|
Date of Presentation:
|
|
09/09/09
|
|
|
|
|
|
|
|
GeoResources, Inc. owns and operates producing oil and gas
properties in the Southwest, Gulf Coast and Williston Basin and
conducts oil and gas exploration, development and production
operations in these areas. Additionally, GeoResources' wholly-owned
subsidiary, Catena Oil & Gas LLC, is the general partner and
operator for two institutionally funded partnerships.
|
|
|
|
GeoResources' reserves, including its direct working interests and
partnership interests, are estimated at 141.4 Bcfe, 49% oil and 75%
proved developed. Current production is approximately 2,300 Bopd and
19.0 MMcfd for its direct interests plus 4.1 MMcfd in its
partnerships. As of July 1, 2009, the Company controlled
approximately 484,000 gross acres and 234,000 net acres.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
GeoVax Labs, Inc.
|
|
|
Ticker Symbol & Exchange:
|
|
OTCB: GOVX
|
|
|
Investor Relations Contact:
|
|
Leslie Loyet
|
|
|
Investor Relations Contact Phone:
|
|
(312) 640-6672
|
|
|
Web:
|
|
www.geovax.com
|
|
|
Date of Presentation:
|
|
09/10/09
|
|
|
|
|
|
|
|
GeoVax is a clinical stage biotechnology company whose primary goal
is to test, license and commercialize its DNA (prime) and MVA
(boost) vaccine regimen for diseases caused by Human
Immunodeficiency Virus (HIV) and other infectious agents. The
immediate mission is to seek expansion of the current clinical trial
(phase 2a) for the preventative version of the vaccine to the "at
risk" human population (phase 2b) and to shepherd a therapeutic
trial (phase 1) in HIV-1 infected subjects, scheduled to begin early
2010. GeoVax's technology is exclusively licensed from Emory
University and was developed in collaboration with Emory
University's Vaccine Center, the National Institutes of Health (NIH)
and the U.S. Centers for Disease Control and Prevention (CDC).
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
GMX Resources Inc.
|
|
|
Ticker Symbol & Exchange:
|
|
GMXR
|
|
|
Investor Relations Contact:
|
|
Michael Rohleder, President
|
|
|
Investor Relations Contact Phone:
|
|
405.254.5838
|
|
|
Web:
|
|
www.gmxresources.com
|
|
|
Date of Presentation:
|
|
09/10/09
|
|
|
|
|
|
|
|
GMXR is a 'Pure Play', E & P Company with one of the most leveraged
Haynesville / Bossier Horizontal Shale Operations in East Texas. The
Company has 465 Bcfe in proved reserves (YE2008), 94% of which are
natural gas. The Company's proved reserves are 81% operated and
consist of 763 gross / 521 net H/B Hz 80 acre un-drilled locations;
8 gross / 8 net H/B producers, and 324 gross / 186.9 net Cotton
Valley Sand ("CVS") producers; 2,657 gross / 1,974 net CVS 20 acre
un-drilled locations; and 45 gross / 37.5 net Travis Peak / Hosston
Sands & Pettit producers. These multiple resource layers provide
high probability and the potential for repeatable, organic growth.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
Gold Horse International, Inc.
|
|
|
Ticker Symbol & Exchange:
|
|
GHII
|
|
|
Investor Relations Contact:
|
|
Adam Wasserman, CFO
|
|
|
Investor Relations Contact Phone:
|
|
800-867-0078 Ext 702
|
|
|
Web:
|
|
www.goldhorseinternational.com
|
|
|
Date of Presentation:
|
|
September 10 from 08:20 to 08:45 AM
|
|
|
|
|
|
|
|
Gold Horse International, Inc. is a multi-faceted business group
specializing in high-growth industries in China, including
construction, real estate and hospitality. Jin Ma Construction Co.,
Ltd. has been providing construction and general contractor services
in Hohhot, Inner Mongolia, China, to both private developers and the
local and regional governments since 1980. Jin Ma Hotel Co., Ltd.
owns, operates and manages the Jin Ma Hotel, a full-service two-star
hotel and banquet facility located in Hohhot. Jin Ma Real Estate
develops residential and commercial properties in the competitive
and growing real estate market in Hohhot.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
Gold One International limited
|
|
|
Ticker Symbol & Exchange:
|
|
ASX/JSE: GDO
|
|
|
Investor Relations Contact:
|
|
Ilja Graulich
|
|
|
Investor Relations Contact Phone:
|
|
27 83 604 0820
|
|
|
Web:
|
|
www.gold1.co.za
|
|
|
Date of Presentation:
|
|
Thursday, 10 September 2009
|
|
|
|
|
|
|
|
Gold One International Limited is an Australian and African gold
resource company listed on the financial markets operated by ASX
Limited and JSE Limited (ticker: GDO). The company was created via
inward listing of Gold One on the JSE and the subsequent acquisition
by Gold One of all the issued ordinary shares in Aflease by way of a
scheme of arrangement. The company's vision is to be the preferred
gold exploration, development and mining company, aiming to provide
superior returns to investors in global markets, supportive of
junior gold mining companies. The company believes that value
accretive geographical diversification is also key to managing risk
and in line with this strategy will continue to review opportunities
in its targeted destinations of Australia, North America and
Southern Africa.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
Gold Resource Corporation
|
|
|
Ticker Symbol & Exchange:
|
|
OTC BB: GORO
|
|
|
Investor Relations Contact:
|
|
Jason Reid
|
|
|
Investor Relations Contact Phone:
|
|
719 330 0258
|
|
|
Web:
|
|
www.goldresourcecorp.com
|
|
|
Date of Presentation:
|
|
Sept. 9, 2009
|
|
|
|
|
|
|
|
Gold Resource Corporation is a mining company focused on production
and pursuing development of select, high-grade gold and silver
projects that feature low operation costs and produce high returns
on capital.
|
|
|
|
|
|
|
The Company has 100% interest in four high-grade gold and silver
properties in Mexico's southern state of Oaxaca.
|
|
|
|
|
|
|
Gold Resource Corporation is positioned to emerge as a low cost gold
producer in 2009 and is engineered from day one to maximize
shareholder value with a focus on cash flow and potential dividends.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
Golden Predator Royalty and Development
|
|
|
Ticker Symbol & Exchange:
|
|
TSX.V:GPD
|
|
|
Investor Relations Contact:
|
|
Ilona Stigrad
|
|
|
Investor Relations Contact Phone:
|
|
604-648-4653
|
|
|
Web:
|
|
www.goldenpredator.com
|
|
|
Date of Presentation:
|
|
September 11th,2009
|
|
|
|
|
|
|
|
Golden Predator's corporate mandate is to establish a
self-fundedgold exploration company with an immediate focus on
exploringand developing world class gold deposits in the Tintina
Gold Belt and the Rocky Mountain Alkalic Gold Province. The Company
seeks internal funding from high grade production in Nevada
augmented by increasing royalty revenues.
|
|
|
|
In the Yukon's prolific Tintina Gold Belt, the Company is currently
drilling Gold Dome, Brewery Creek and Antimony Mountain. Golden
Predator Royalty and Development Corp. continues to expand its
interests in this area through exploration and property acquisition.
In Nevada and Wyoming drilling plans progress on several advanced
projects.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
Gulf Resources, Inc.
|
|
|
Ticker Symbol & Exchange:
|
|
OTC BB: GFRE
|
|
|
Investor Relations Contact:
|
|
David Wong, VP Finance
|
|
|
Investor Relations Contact Phone:
|
|
Crocker Coulson, CCG - 1 (646) 213-1915
|
|
|
Web:
|
|
www.gulfresourcesinc.cn
|
|
|
Date of Presentation:
|
|
4:55 PM on Thu. Sept. 10, 2009
|
|
|
|
|
|
|
|
Gulf Resources, Inc. ("Gulf Resources" or the "Company" ) is a
leading provider of bromine and specialty chemical products in the
People's Republic of China ("PRC" ). The Company operates through its
two wholly-owned subsidiaries; Shouguang City Haoyuan Chemical
Company Limited ("SCHC" ), which primarily produces and distributes
bromine and crude salt, and Shouguang Yuxin Chemical Industry Co.,
Limited ("SYCI" ), which focuses on manufacturing and selling
chemical products. Elemental bromine is used to manufacture a wide
range of compounds utilized in chemical, manufacturing,
pharmaceutical, and agricultural industries. The Company's chemical
products are currently utilized in a variety of applications,
including oil and gas field exploration, papermaking chemical
agents, and inorganic chemicals.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
Gulfstream International Airlines
|
|
|
Ticker Symbol & Exchange:
|
|
GIA:AMEX
|
|
|
Investor Relations Contact:
|
|
Jennifer K. Zimmons
|
|
|
Investor Relations Contact Phone:
|
|
212-838-1444
|
|
|
Web:
|
|
www.gulfstreamair.com
|
|
|
Date of Presentation:
|
|
Sep 9th from 02:50 to 03:15 PM
|
|
|
|
|
|
|
|
Gulfstream International Airlines is a profitable regional air
carrier based in Fort Lauderdale, Florida with 20 years operating
experience. The Company specializes in providing travelers access to
niche locations not typically covered by major carriers including:
Bahamas, inter-Florida, Cuba, and the Cleveland area. With 150+
daily flights to second-tier routes in 21 cities, Gulfstream's fleet
of 19-seat planes, unique in-house technology platform, and
marketing team makes the Company the dominant player in their space.
Furthermore, the continuing retrenchment of other airlines to their
hubs provides several additional lucrative city-to-city routes that
would be otherwise unprofitable for other carriers.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
Guyana Goldfields Inc.
|
|
|
Ticker Symbol & Exchange:
|
|
TSX. GUY
|
|
|
Investor Relations Contact:
|
|
Jacqueline Wagenaar
|
|
|
Investor Relations Contact Phone:
|
|
416-628-5936
|
|
|
Web:
|
|
www.guygold.com
|
|
|
Date of Presentation:
|
|
September 10, 2009 @ 10:50am
|
|
|
|
|
|
|
|
Guyana Goldfields Inc. is a well-financed Canadian-based junior
mineral exploration company focused on the exploration and
development of gold deposits in the mining-friendly Guiana Shield in
South America with a land position totaling 350,000 acres in Guyana.
The Company is currently undertaking technical studies to advance
and develop its 100% interest in the Aurora Gold Project in Guyana
with a current resource of 5.4 million oz.
|
|
|
|
GUY is currently utilizing six drills at site as part of the
technical work for the feasibility study and continued exploration
efforts. GUY is ready to start Development in Q2 2010 after
completing the Economic and Social Impact Assessment, Definitive
Feasibility Study, Permitting, and Project Financing.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
Hana Biosciences, Inc.
|
|
|
Ticker Symbol & Exchange:
|
|
NASDAQ: HNAB
|
|
|
Investor Relations Contact:
|
|
Rebecca Birbach
|
|
|
Investor Relations Contact Phone:
|
|
650-588-6641
|
|
|
Web:
|
|
http://www.hanabiosciences.com
|
|
|
Date of Presentation:
|
|
09/10/09
|
|
|
|
|
|
|
|
Hana Biosciences, Inc. (NASDAQ: HNAB) is a South San Francisco,
CA-based biopharmaceutical company focused on acquiring, developing,
and commercializing innovative products to strengthen the foundation
of cancer care. The company is committed to creating value by
building a best in-class team, accelerating the development of lead
product candidates, expanding its pipeline by being an alliance
partner of choice, and nurturing a unique company culture.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
Hecla Mining Company
|
|
|
Ticker Symbol & Exchange:
|
|
HL:NYSE
|
|
|
Investor Relations Contact:
|
|
Don Poirier, VP
|
|
|
Investor Relations Contact Phone:
|
|
208-769-4128
|
|
|
Web:
|
|
www.hecla-mining.com
|
|
|
Date of Presentation:
|
|
09/09/09
|
|
|
|
|
|
|
|
Established in 1891 in northern Idaho's Silver Valley, Hecla has
long been known in the United States as a quality producer of silver
and gold. Hecla operates two underground mines, Lucky Friday in
northern Idaho and Greens Creek near Juneau, Alaska, and is the
oldest U.S.-based precious metals miner in North America. Hecla
expects to produce 10-11 million ounces of silver in 2009 and also
produces approximately 60,000 ounces of gold per year plus
lead-zinc. Hecla has two development projects, San Juan Silver in
Colorado and San Sebastian near Durango, Mexico. Hecla has highly
prospective exploration opportunities in the camps where it operates
as well as within the development projects in Colorado and Mexico.
Hecla trades on the New York Stock Exchange and its stock symbol is
"HL."
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
Helsinn Healthcare SA
|
|
|
Investor Relations Contact:
|
|
Ricccardo Braglia
|
|
|
Investor Relations Contact Phone:
|
|
00 41 (0)91 985 21 21
|
|
|
Web:
|
|
www.helsinn.com
|
|
|
Date of Presentation:
|
|
Sept. 9, 2009 4.05pm EDT (10.05pm Swiss time, 9.05pm UK time)
|
|
|
|
|
|
Helsinn Healthcare SA announced that Mr.Riccardo Braglia, CEO, will
present an overview of the company, products and corporate goals at
Rodman & Renshaw 11th Annual Healthcare Conference, New York, USA,
on September 9th 2009 at 4:05pm EDT (10.05pm Swiss time, 9.05pm UK
time). The presentation will be webcast live and can be accessed
through the web site (www.wsw.com/webcast/rrshq15/helsinn)
(available for 90 days).
|
|
|
|
Helsinn (www.helsinn.com) is a privately owned Swiss-based
pharmaceutical group with subsidiaries in USA and Ireland. Core
business: oncology, supportive care and pain inflammation. Business
strategy: in-license early stage new chemical entities, complete
their development up to market approvals and out-license to its
worldwide network of partners. Active pharmaceutical ingredients and
drug products are manufactured at Helsinn's cGMP facilities.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
Home BancShares, Inc.
|
|
|
Ticker Symbol & Exchange:
|
|
HOMB / NASDAQ
|
|
|
Investor Relations Contact:
|
|
Brian Davis
|
|
|
Investor Relations Contact Phone:
|
|
501-328-4770
|
|
|
Web:
|
|
www.homebancshares.com
|
|
|
Date of Presentation:
|
|
09/09/09
|
|
|
|
|
|
|
|
Home BancShares, Inc. is a bank holding company headquartered in
Conway, Arkansas. The Company is primarily engaged in providing a
full range of banking services to individual and corporate customers
through its wholly owned community bank subsidiary - Centennial
Bank. During 2009, the Company completed the combination of its
former bank charters into a single charter, adopting Centennial Bank
as the common name. The Bank has locations in central Arkansas,
north central Arkansas, southern Arkansas, the Florida Keys and
southwestern Florida.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
Hong Kong Highpower Technology, Inc.
|
|
|
Ticker Symbol & Exchange:
|
|
NYSE Amex
|
|
|
Investor Relations Contact:
|
|
Tricia Ross
|
|
|
Investor Relations Contact Phone:
|
|
916-939-7285
|
|
|
Web:
|
|
http://www.haopengbattery.com/
|
|
|
Date of Presentation:
|
|
09/09/09
|
|
|
|
|
|
|
|
Hong Kong Highpower Technology is a profitable growth company that
develops, manufactures and markets nickel-metal hydride (Ni-MH) and
lithium-ion (Li-ion) rechargeable batteries and related products for
consumer and industrial applications. The Company's products are
distributed worldwide for use in various electronic products and
emergency power supplies such as digital and communication products,
power tools, toys, notebook computers, cell phones, GPS navigation
systems, military products, electronic bikes and medical devices.
The Company's manufacturing and product development facilities are
located in Shenzhen, Guangdong Province, PRC, which facilitates low
labor costs and easy access to land and raw materials, as well as
additional cost and cycle time advantages garnered by proximity to
electronics supply chains and end-markets.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
HORIZON FINANCIAL
|
|
|
Ticker Symbol & Exchange:
|
|
NASDAQ GS: HRZB
|
|
|
Investor Relations Contact:
|
|
Rich Jacobson, President & CEO
|
|
|
Investor Relations Contact Phone:
|
|
360-733-3050
|
|
|
Web:
|
|
www.horizonbank.com
|
|
|
Date of Presentation:
|
|
09/10/09
|
|
|
|
|
|
|
|
Horizon Financial Corp. is a $1.36 billion state-chartered bank
holding company based in Bellingham, Washington. Its primary
subsidiary, Horizon Bank, is a regional presence serving customers
for 87 years operating 18 full-service offices; four commerical and
real estate loan centers throughout Whatcom, Skagit, Snohomish and
Pierce counties in Washington.
|
|
|
|
Selected Fiscal First Quarter 2010 Highlights include:
|
|
|
|
|
|
- Core Deposits generated year-over-year growth increasing $27.7
million compared to June of 2008, and increased $4.8 million since
March, 2009.
|
|
|
|
- Total assets were $1.36 billion at 6/30/2009
|
|
|
|
|
|
|
|
- Total risk-based capital ratio was 5.2% and Tier 1 capital ratio
equaled 3.17% at 6/30/09.
|
|
|
|
|
|
- Horizon actively pursuing capital infusion.
|
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
ImmunoCellular Therapeutics, Ltd.
|
|
|
Ticker Symbol & Exchange:
|
|
IMUC OTC:BB
|
|
|
Investor Relations Contact:
|
|
Gary Nash
|
|
|
Investor Relations Contact Phone:
|
|
212-732-4300
|
|
|
Web:
|
|
www.imuc.com
|
|
|
Date of Presentation:
|
|
09/11/09
|
|
|
|
|
|
|
|
IMUC is a Los Angeles-based clinical-stage company that is
developing immune based therapies for the treatment of brain and
other cancers. The company's "off the shelf" therapeutic vaccine
product candidate targeting cancer stem cells for multiple cancer
indications is expected to enter clinical trials early next year.
IMUC is in pre-clinical development of a monoclonal antibody product
candidate for the treatment of small cell lung cancer and pancreatic
cancer, and is also evaluating its platform technology for
monoclonal antibody discovery using differential immunization for
diagnosing and treating multiple types of cancer.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
IncrediMail Inc.
|
|
|
Ticker Symbol & Exchange:
|
|
NASDAQ:MAIL
|
|
|
Investor Relations Contact:
|
|
Jeff Holzmann, President
|
|
|
Investor Relations Contact Phone:
|
|
212.682.1995
|
|
|
Web:
|
|
www.incredimail-corp.com
|
|
|
Date of Presentation:
|
|
Sep 11th, 2009
|
|
|
|
|
|
|
|
IncrediMail Ltd. (NASDAQ: MAIL) is an internet company founded in
1999 in Tel Aviv, Israel. It designs, markets and delivers
high-end personal desktop software. The company's award winning
e-mail client product, IncrediMail Premium, is sold in over 100
countries in 10 different languages. Other products include
Magentic, a wallpaper and screensaver software for digital
personal photos and HiYo, a graphic add-on to instant messaging
software. The company went public in January 2006 with an IPO on
the US NASDAQ exchange. It currently employs about 110 people in
its Tel Aviv and New York offices. In July 2008, IncrediMail
signed a contract with Google, making it a partner in Google's
"AdSense for Search" program.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
InterAmerican Acquisition Group/CNC Dev
|
|
|
Ticker Symbol & Exchange:
|
|
OTC BB: IAQG, IAQGW
|
|
|
Investor Relations Contact:
|
|
William Morro, CEO
|
|
|
Investor Relations Contact Phone:
|
|
Crocker Coulson, CCG, 1(646) 213-1915
|
|
|
Web:
|
|
www.cncdev.com
|
|
|
Date of Presentation:
|
|
10:50AM on Thurs. Sept. 10, 2009
|
|
|
|
|
|
|
|
IAG was formed for the purpose of acquiring, through a merger, stock
exchange, asset acquisition or other similar business combination,
an unidentified operating business. It formed a subsidiary, CNC
Development Ltd. for the sole purpose of effecting a redomestication
merger and acquiring Sing Kung. Sing Kung Limited (BVI), through its
PRC operating subsidiary, forms and leads consortiums to deliver
comprehensive city planning and infrastructure build-outs to
selected municipalities throughout China. The company's
"Build-Transfer" business model allows local governments to overcome
financial and project management constraints and to quickly unlock
economic development potential and property value.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
INX Inc.
|
|
|
Ticker Symbol & Exchange:
|
|
INXI
|
|
|
Investor Relations Contact:
|
|
Monica Kleypas
|
|
|
Investor Relations Contact Phone:
|
|
713-795-2168
|
|
|
Web:
|
|
http://www.inxi.com
|
|
|
Date of Presentation:
|
|
09/11/09
|
|
|
|
|
|
|
|
INX Inc. provides technology infrastructure solutions for
enterprise-class organizations in the United States. Its solutions
include network infrastructure solutions, such as network routing
and switching, wireless networking, and network security
solutions; unified communications solutions, including Internet
protocol (IP) network-based voice or telephone solutions, as well
as IP network-based video communications solutions; and data
center solutions, such as network storage solutions and data
center server virtualization solutions. It also provides planning,
design, and implementation professional services, as well as
managed support services and technology hosting services. The
company also offers IP voice and video communications solutions
and network storage solutions.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
Iteris, Inc.
|
|
|
Ticker Symbol & Exchange:
|
|
ITI NYSE Amex
|
|
|
Investor Relations Contact:
|
|
Brett Maas
|
|
|
Investor Relations Contact Phone:
|
|
646-536-7331, brett@haydenir.com
|
|
|
Web:
|
|
www.iteris.com
|
|
|
Date of Presentation:
|
|
09/10/09
|
|
|
|
|
|
|
|
Iteris, Inc. is a leader in the traffic management market focused
on the development and application of advanced technologies that
reduce traffic congestion, minimize the environmental impact of
traffic congestion, and improve the safety of surface
transportation systems infrastructure. Combining outdoor image
processing, traffic engineering, and information technology,
Iteris offers a broad range of Intelligent Transportation Systems
and driver safety solutions to customers worldwide. Iteris is
headquartered in Santa Ana, California with offices throughout
North America, Europe, and Asia. Investors are encouraged to
contact us at 888-329-4483, or at www.iteris.com.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
Javelin Pharmaceuticals, Inc.
|
|
|
Ticker Symbol & Exchange:
|
|
NYSE Amex: JAV
|
|
|
Investor Relations Contact:
|
|
Rick Pierce
|
|
|
Investor Relations Contact Phone:
|
|
617-349-4500
|
|
|
Web:
|
|
www.javelinpharmaceuticals.com
|
|
|
Date of Presentation:
|
|
September 9, 2009 at 2:50pm
|
|
|
|
|
|
|
|
With corporate headquarters in Cambridge, MA, Javelin applies
innovative proprietary technologies to develop new drugs and
improved formulations of existing drugs to target unmet and
underserved medical needs in the acute pain management market. The
Company has one marketed drug in the UK and three drug candidates in
US Phase 3 clinical development. For additional information about
Javelin, please visit the Company's website at
http://www.javelinpharmaceuticals.com.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
Jiangbo Pharmaceuticals, Inc.
|
|
|
Ticker Symbol & Exchange:
|
|
OTCBB: JGBO
|
|
|
Investor Relations Contact:
|
|
Ms. Elsa Sung
|
|
|
Investor Relations Contact Phone:
|
|
(954)727-8435
|
|
|
Web:
|
|
www.jiangbopharma.com
|
|
|
Date of Presentation:
|
|
09/09/09
|
|
|
|
|
|
|
|
Jiangbo Pharmaceuticals, Inc. engages in research, development,
production, marketing and sales of medicines in P.R. China. The
Company is well positioned to benefit from rapidly growing
pharmaceutical market in China by its well known brand, experienced
management, skilled workforce and extensive distribution network. It
has sales representatives located in all major commerce areas across
China. The Company currently has 28 products in its product
portfolio and its best selling products include Clarithromycin
sustained-release tablets, Itopride Hydrochloride granules, Baobaole
Chewable Tablets, Radix Isatidis Dispersible Tablets and Laiyang
Pear Cough Syrup.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
KaloBios Pharmaceuticals, Inc.
|
|
|
Investor Relations Contact:
|
|
Consuelo Alatorre
|
|
|
Investor Relations Contact Phone:
|
|
(650) 243-3120
|
|
|
Web:
|
|
www.kalobios.com
|
|
|
Date of Presentation:
|
|
09/09/09
|
|
|
|
|
|
|
|
KaloBios focuses on novel, first in class, monoclonal antibodies. We
recently completed four Phase 1/2 clinical trials with KB002, an
anti-GM-CSF antibody, including one in rheumatoid arthritis and
another for persistent asthma. We also completed Phase 1 testing for
KB003, a Humaneered version of the KB002 antibody, and plan to move
this forward into Phase 2b studies soon.
|
|
|
|
KaloBios also recently completed two Phase 1/2 clinical trials with
KB001, an anti-Pseudomonas antibody; one in France for intensive
care patients on mechanical ventilators and the other in the US in
patients with cystic fibrosis. Data for these two trials is expected
3Q 2009.
|
|
|
|
KaloBios also plans to file an IND for KB004 in 1H2010, an antibody
targeted against a novel epitope (EphA3). We plan to test this in
hematologic malignancies and solid tumors.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
Kodiak Oil & Gas Corp
|
|
|
Ticker Symbol & Exchange:
|
|
KOG
|
|
|
Investor Relations Contact:
|
|
NYSE
|
|
|
Investor Relations Contact Phone:
|
|
David Charles 303-757-2510
|
|
|
Web:
|
|
www.kodiakog.com
|
|
|
Date of Presentation:
|
|
09/09/2009 at 11:15 a.m. (EDT)
|
|
|
|
|
|
|
|
Denver-based Kodiak Oil & Gas is an independent energy exploration
and development company focused on exploring, developing and
producing oil and natural gas in the Williston and Green River
Basins in the U.S. Rocky Mountains. For further information, please
visit www.kodiakog.com. The Company's common shares are listed for
trading on the NYSE Amex exchange under the symbol: "KOG."
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
Labrador Iron Mines Holdings Limited
|
|
|
Ticker Symbol & Exchange:
|
|
LIM: TSX
|
|
|
Investor Relations Contact:
|
|
Donna Yoshimatsu
|
|
|
Investor Relations Contact Phone:
|
|
647-728-4119
|
|
|
Web:
|
|
www.labradorironmines.ca
|
|
|
Date of Presentation:
|
|
09/10/09
|
|
|
|
|
|
|
|
Labrador Iron Mines Holdings Limited is focused on the development
and production of eight direct-shipping (DSO) iron ore deposits
located across a 100 km strike length in the Labrador Trough of the
Province of Newfoundland and Labrador near Schefferville, Quebec.
The Company's properties are part of the historic Schefferville area
iron ore district from which over 150 million tons of iron ore was
mined by the Iron Ore Company of Canada (IOC) from 1954 to 1982. The
Company is on track to be the first to reactivate DSO iron ore
production in Labrador commencing in 2010. The project benefits from
the significant existing infrastructure including power, water,
airport, roads, 565 km of rail and a deep seaport that exports over
20 million tonnes of iron products annually.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
MannKind Corporation
|
|
|
Ticker Symbol & Exchange:
|
|
MNKD
|
|
|
Investor Relations Contact:
|
|
Matthew (Matt) Pfeffer
|
|
|
Investor Relations Contact Phone:
|
|
Roberta Dey - Conf. Coord 661-775-554
|
|
|
Web:
|
|
www.mannkindcorp.com
|
|
|
Date of Presentation:
|
|
September 10 at 11:40am Eastern
|
|
|
|
|
|
|
|
MannKind Corporation focuses on the development of therapeutic
products for patients with diseases such as diabetes and cancer. We
recently submitted an application to the FDA requesting approval of
AFRESA Inhalation Powder for the treatment of adults with type 1 or
type 2 diabetes mellitus.
|
|
|
|
AFRESA is an ultra rapid acting insulin with a unique
pharmacokinetic profile. AFRESA immediately dissolves upon contact
with the lung, releasing insulin monomers that rapidly enter the
bloodstream. AFRESA achieves peak insulin levels within 12-14
minutes, effectively mimicking the release of meal-time insulin
observed in healthy individuals, but which is absent or impaired in
diabetics.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
MEDIS TECHNOLOGIES LTD.
|
|
|
Ticker Symbol & Exchange:
|
|
OTC: MDTL.PK
|
|
|
Investor Relations Contact:
|
|
Michael Mason
|
|
|
Investor Relations Contact Phone:
|
|
212.691.8087
|
|
|
Web:
|
|
www.medistechnologies.com
|
|
|
Date of Presentation:
|
|
09/10/09
|
|
|
|
|
|
|
|
Medis, headquartered in New York City, is the first company in the
world to design, develop and market a portable liquid fuel cell
capable of providing electrical power to mobile electronics. Medis
is the only portable fuel cell ever manufactured in commercial
quantity with 150,000 working units produced to date.
|
|
|
|
Medis has an impressive IP portfolio, and dedicates considerable
resources to maintaining and protecting its rights. The company has
several international patents, including patents in Russia.
|
|
|
|
Medis is targeting consumer markets, US and international military
markets, and US departments and agencies including FEMA, Border
Patrol and Coast Guard.
|
|
|
|
Medis is committed to the environment and green technology - its
Power Pack does not contain or use environmentally damaging
materials or chemicals and is completely recyclable.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
Medusa Mining Limited
|
|
|
Ticker Symbol & Exchange:
|
|
MML (ASX and AIM)
|
|
|
Investor Relations Contact:
|
|
Geoff Davis
|
|
|
Investor Relations Contact Phone:
|
|
+618 9367 0601
|
|
|
Web:
|
|
www.medusamining.com.au
|
|
|
Date of Presentation:
|
|
09/10/09
|
|
|
|
|
|
|
|
•Philippines focused gold producer, no debt, no hedging
|
|
|
|
|
|
•Lowest cash cost producer listed on ASX and AIM
|
|
|
|
|
|
•Sixth largest gold producer by market cap on ASX
|
|
|
|
|
|
•Long term cash costs US$200/oz
|
|
|
|
|
|
•2009-2010 FY production 47,869ozs at US$213/oz cash cost
|
|
|
|
|
|
•Total resources 2.03Mozs
|
|
|
- Co-O Mine 1.38Mozs at 10.8g/t gold and expanding
|
|
|
- Bananghilig Deposit 650,000ozs at 1.3g/t gold and open
|
|
|
|
|
|
•Co-O Mine reserve 500,000ozs at 14.9g/t gold
|
|
|
|
|
|
•On schedule for 100,000ozs annualized production Q1 07/02/05
|
|
|
|
|
|
•Multiple deposit discovery potential in 880km²
|
|
|
- Additional vein deposits
|
|
|
- Additional disseminated gold deposits
|
|
|
- Copper deposits - drilling underway at Lingig with good initial
results
|
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
Midnight Oil Exploration Ltd.
|
|
|
Ticker Symbol & Exchange:
|
|
MOX - TSX
|
|
|
Investor Relations Contact:
|
|
Jo Ellen Krchnak
|
|
|
Investor Relations Contact Phone:
|
|
403-303-8510
|
|
|
Web:
|
|
www.midnightoil.ca
|
|
|
Date of Presentation:
|
|
September 9, 2009 at 2:00pm ET
|
|
|
|
|
|
|
|
Midnight Oil Exploration Ltd. is a junior-sized energy company with
a strong technical team and an excellent asset base comprising the
high potential resource play in the Deep Basin of Alberta and a high
value light oil production base at Red Earth. We hold over 100
sections in our Deep Basin resource play focused on the
multi-layered tight gas potential of the Cadomin and Nikanassin
stacked with the high impact conventional gas reservoirs. Our light
oil production provides a solid cash flow to capitalize our Deep
Basin drilling. We have a proven track record and it is our
experience, expertise, innovative operational and business skills,
solid balance sheet, light oil production and tremendous resource
play prospect inventory that positions Midnight well for the future,
contributing strong economics and low risk repeatability.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
MINEFINDERS CORPORATION LTD
|
|
|
Ticker Symbol & Exchange:
|
|
NYSE AMEX:MFNTSX:MFL
|
|
|
Investor Relations Contact:
|
|
Mike Wills
|
|
|
Investor Relations Contact Phone:
|
|
(604)- 687-6263
|
|
|
Web:
|
|
www.minefinders.com
|
|
|
Date of Presentation:
|
|
Thursday 10 Sept. @ 2:50 - 3:15pm
|
|
|
|
|
|
|
|
Minefinders is a precious metals mining and exploration company. The
Company's flagship Dolores Mine in Mexico commenced production of
gold and silver in November, 2008 and is expected to produce more
than 1.7 million ounces of gold and 64.4 million ounces of silver
from heap-leach operations over a 15.5 year mine life.
|
|
|
|
Minefinders Corporation also has property interests in Northern
Sonora, including the La Bolsa deposit, the Real Viejo silver
prospect, and the Planchas de Plata prospect. The company is
headquartered in Vancouver, Canada.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
Minnow Medical
|
|
|
Investor Relations Contact:
|
|
Keith Lippert
|
|
|
Investor Relations Contact Phone:
|
|
Lippert Heilshorn & Associates 8383777
|
|
|
Web:
|
|
www.minnowmedical.com
|
|
|
Date of Presentation:
|
|
09/10/09
|
|
|
|
|
|
|
|
Minnow Medical is developing proprietary products to treat artery
disease which can occur throughout the body, including the heart,
neck, head and lungs. The Company is initially targeting Peripheral
Artery Disease, a highly prevalent form of cardiovascular disease
found mostly in the lower extremities or legs that impacts 27
million people in North America and Europe. The Company has
developed a patent-pending disposable catheter therapy that
precisely treats only the atherosclerotic plaque present within an
artery. On April 15, 2009, Minnow Medical announced it had received
the CE Mark clearing its disposable catheter for marketing in the
European Union.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
Mission New Energy
|
|
|
Ticker Symbol & Exchange:
|
|
MBT (ASX)
|
|
|
Investor Relations Contact:
|
|
Jennifer K.Zimmons, Ph.D.
|
|
|
Investor Relations Contact Phone:
|
|
212-838-1444
|
|
|
Web:
|
|
www.missionnewenergy.com
|
|
|
Date of Presentation:
|
|
Sept 10, 2009 - 10:50am-11:15am
|
|
|
|
|
|
|
|
Mission NewEnergy Limited is a global renewable energy provider with
operations in Australia, Malaysia, India and Mauritius. Biodiesel
refineries are located at Kuantan Port in Malaysia. Currently
operating a 100,000 tonne per annum biodeisel facility, Mission's
second refinery, adjacent to the first facility, will be completed
early 2009 providing for a combined capacity of 350,000 tonnes of
biodeisel per annum. Mission has a well-developed upstream feedstock
business in India, focused on the use of Jatropha Curcas, a
non-food, drought resistent crop. The Company's wind power business
provides electricity to the state utility of India.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
MTI MicroFuel Cells, Inc.
|
|
|
Ticker Symbol & Exchange:
|
|
MKTY
|
|
|
Investor Relations Contact:
|
|
Scott Estro
|
|
|
Investor Relations Contact Phone:
|
|
(415) 233 6814
|
|
|
Web:
|
|
www.mtimicrofuelcells.com
|
|
|
Date of Presentation:
|
|
Sept. 09, 2009
|
|
|
|
|
|
|
|
MTI MicroFuel Cells Inc., a subsidiary of Mechanical Technology,
Inc. (OTC:MKTY) is commercializing the Mobion micro fuel cell in
2010. An off-the-grid mobile power source that uses a "green"
renewable fuel called methanol. To penetrate the $70B worldwide
battery market, the company has signed agreements with 6 global OEM
partners that include Samsung Electronics and a LOI with Duracell.
Mobion technology is also protected by 110 patent applications with
52 granted. Mobion has a flexible architecture suited for various
consumer, industrial, and military markets. The company was recently
awarded $2.4 million by US DOE to accelerate micro fuel cell
deployment.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
Nanostart AG
|
|
|
Ticker Symbol & Exchange:
|
|
NNS.GR
|
|
|
Investor Relations Contact:
|
|
Vanessa Mieschke
|
|
|
Investor Relations Contact Phone:
|
|
0049 69 21 93 96 116
|
|
|
Web:
|
|
www.nanostart.de
|
|
|
Date of Presentation:
|
|
09.08.2009
|
|
|
|
|
|
|
|
Nanostart, a nanotechnology investment company, announced today that
Marco Beckmann, CEO, is scheduled to present at the 2009 Rodman &
Renshaw Conference being held in New York. The presentation is
scheduled for 2:00 p.m. (EDT) on Wednesday, September 09, 2009 at
the New York Palace Hotel. Marco Beckmann will provide an overview
on Nanostart and will highlight current developments of the company
and its portfolio. The German based Nanostart invests in young,
up-and-coming nanotechnology companies throughout the world. These
are companies seeking to commercialize highly innovative products or
processes mostly in growth markets such as cleantech, life sciences
and healthcare. It currently holds 9 companies from the US, Europe
and Asia with groundbreaking technologies in its portfolio.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
NAPCO Security Technologies, Inc.
|
|
|
Ticker Symbol & Exchange:
|
|
NASDAQ: NSSC
|
|
|
Investor Relations Contact:
|
|
Donald C. Weinberger
|
|
|
Investor Relations Contact Phone:
|
|
(212) 370-4500
|
|
|
Web:
|
|
www.napcosecurity.com
|
|
|
Date of Presentation:
|
|
09/09/09
|
|
|
|
|
|
|
|
NAPCO Security Technologies, Inc. is one of the world's leading
manufacturers of technologically advanced electronic security
equipment including intrusion and fire alarm systems, access control
and door locking systems. The Company consists of NAPCO plus three
wholly-owned subsidiaries: Alarm Lock, Continental Instruments, and
Marks USA. The products are installed by security professionals
worldwide in commercial, industrial, institutional, residential and
government applications. NAPCO products have earned a reputation for
technical excellence, reliability and innovation, poising the
Company for growth in the rapidly expanding electronic security
market, a multi-billion dollar market.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
Neah Power Systems, Inc.
|
|
|
Ticker Symbol & Exchange:
|
|
OTCBB: NPWZ
|
|
|
Investor Relations Contact:
|
|
Michael Selsman
|
|
|
Investor Relations Contact Phone:
|
|
310-553-5732 ms@publiccommunications.biz
|
|
|
Web:
|
|
www.neahpower.com
|
|
|
Date of Presentation:
|
|
September 11, 2009, 10 am
|
|
|
|
|
|
|
|
Neah Power Systems, Inc. (NPWZ) is developing long-lasting,
efficient and safe power solutions for the commercial, consumer and
military portable electronic devices. Neah uses a unique, patented,
silicon-based design for its micro fuel cells that enable higher
power densities, lower cost and compact form-factors, and can run in
aerobic and anaerobic modes. The company is also developing energy
storage solutions based on this technology, as well as off-the-grid
renewable energy solutions.
|
|
|
|
Previous investors in Neah Power include Intel Capital, Novellus
Systems, and other leading VC firms. The company has also won
various accolades and federal grants.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
Neptune Marine Services Limited
|
|
|
Ticker Symbol & Exchange:
|
|
ASX : NMS
|
|
|
Investor Relations Contact:
|
|
Neptune Marine
|
|
|
Investor Relations Contact Phone:
|
|
61 8 9424 1111
|
|
|
Web:
|
|
www.neptunems.com
|
|
|
Date of Presentation:
|
|
09/09/09
|
|
|
|
|
|
|
|
Neptune Marine Services is emerging as one of Australia's leading
providers of integrated solutions to the international oil and gas,
marine and renewable energy industries. Neptune's primary focus is
the offshore oil and gas sector where its comprehensive suite of
subsea services can be tailored to provide engineered solutions that
meet the demanding and diverse requirements of both new 'greenfield'
and existing inspection, repair and maintenance projects.
Headquartered in Perth, Western Australia, Neptune also has
international operations spanning Australia, Asia, the United States
and United Kingdom.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
Neurologix, Inc.
|
|
|
Ticker Symbol & Exchange:
|
|
NRGX.OB
|
|
|
Investor Relations Contact:
|
|
John E. Mordock, Pres. & CEO
|
|
|
Investor Relations Contact Phone:
|
|
Marc L. Panoff, CFO, Treas. & Sec.
|
|
|
Web:
|
|
www.neurologix.net
|
|
|
Date of Presentation:
|
|
09/09/09
|
|
|
|
|
|
|
|
Neurologix, Inc. (NRGX.OB) is a clinical-stage biotechnology company
dedicated to the discovery, development, and commercialization of
life-altering gene transfer therapies for serious disorders of the
brain and Central Nervous System (CNS). Neurologix's therapeutic
approach is built upon the groundbreaking research of its scientific
founders and advisors, whose accomplishments have formed the
foundation of gene therapy for neurological illnesses. Current
company programs address such conditions as Parkinson's disease,
Huntington's disease and epilepsy, all of which are large markets
not adequately served by current therapeutic options.
|
|
201 592 6451
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
NeuroSearch A/S
|
|
|
Ticker Symbol & Exchange:
|
|
NEUR
|
|
|
Investor Relations Contact:
|
|
Hanne Leth Hillman
|
|
|
Investor Relations Contact Phone:
|
|
45 4460 8212
|
|
|
Web:
|
|
www.neurosearch.dk
|
|
|
Date of Presentation:
|
|
09/11/09
|
|
|
|
|
|
|
|
The core business of the company covers the development of novel
pharmaceutical agents, based on a broad and well-established drug
discovery platform focusing on ion channels and central nervous
system (CNS) disorders. The drug pipeline comprises seven clinical
(Phase I-III) development programmes: Huntexil (Pridopidine) for
Huntington's disease (Phase III), tesofensine for obesity (Phase
III ready), ABT-894 for ADHD (Phase II) in partnership with
Abbott, ACR343 for schizophrenia (Phase II ready), ACR325 to treat
dyskinesias in Parkinson's disease.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
New Generation Biofuels
|
|
|
Ticker Symbol & Exchange:
|
|
NASDAQ: NGBF
|
|
|
Investor Relations Contact:
|
|
Ed Job, CFA
|
|
|
Investor Relations Contact Phone:
|
|
ed.job@ccgir.com, (646) 213-1914
|
|
|
Web:
|
|
http://www.newgenerationbiofuels.com/
|
|
|
Date of Presentation:
|
|
09/11/09
|
|
|
|
|
|
|
|
New Generation Biofuels Holdings, Inc. is a renewable fuels provider
that is marketing a new class of "second generation" biofuels for
use in diesel fuel applications, including power generation,
commercial and industrial processing, heating and marine
transportation.
|
|
|
|
The company produces biofuels using a proprietary blending
technology that is less expensive than the complex chemical reaction
process used to produce traditional biodiesel. This technology
provides the flexibility to produce biofuel from multiple
feedstocks, including non-edible raw.
|
|
|
|
New Generation Biofuels' business model calls for the establishment
of biofuel production facilities directly and through sublicensing
of its technology to qualified licensees.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
New Gold Inc.
|
|
|
Ticker Symbol & Exchange:
|
|
NGD - TSX and NYSE
|
|
|
Investor Relations Contact:
|
|
Melanie Hennessey
|
|
|
Investor Relations Contact Phone:
|
|
604-639-0022
|
|
|
Web:
|
|
www.newgold.com
|
|
|
Date of Presentation:
|
|
09/09/09
|
|
|
|
|
|
|
|
New Gold Inc. is an intermediate gold producer with cash flow
positive operating assets in the United States, Mexico and Australia
and development projects in Canada and Chile. The company has a
solid platform for profitable growth with a strong financial
position to fund its growth strategy and a talented management team
and Board of Directors who have the experience to continue to
execute on New Gold's vision of becoming a million ounce, low cost
gold producer.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
Nido Petroleum Limited
|
|
|
Investor Relations Contact:
|
|
Dominique Schelfhout
|
|
|
Investor Relations Contact Phone:
|
|
61 8 9474 0000
|
|
|
Date of Presentation:
|
|
Friday 11th September 2009
|
|
|
|
|
|
|
|
Nido Petroleum Ltd (ASX:NDO) is an ASX-listed oil and gas
exploration and production company focused on Southeast Asia. Its
asset base comprises the largest contiguous exploration footprint
(about 3 million hectares) in offshore northwest Palawan, the most
prolific basin in Philippines which contains the giant Malampaya gas
field.
|
|
|
|
Nido has production (22.8% in Galoc oil field), development (60% in
Tindalo and Yakal) and exploration (50% deepwater Palawan) assets.
|
|
|
|
An internationally experienced Board of Directors and Management
Teams in Perth and Manila continue to deliver on strategy. The
Philippines offers the best fiscal regime for the upstream oil and
gas sector in the region.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
Norton Gold Fields Limited
|
|
|
Ticker Symbol & Exchange:
|
|
NGF (Australia)
|
|
|
Investor Relations Contact:
|
|
Simon Brodie
|
|
|
Investor Relations Contact Phone:
|
|
Simon Brodie 61 (0) 411 558 544
|
|
|
Web:
|
|
www.nortongoldfields.com.au
|
|
|
Date of Presentation:
|
|
09/09/09
|
|
|
|
|
|
|
|
Norton Gold Fields is one of the largest Australian gold producers.
The Company produces around 150,000 oz/year from its open cut
operations at Paddington near Kalgoorlie in Western Australia.
Paddington has approximately 1.2mm oz of reserves and over 6mm oz of
resources.
|
|
|
|
Paddington's annual output is planned to increase towards 200,000 oz
over the next 12 months with the development of the Homestead
underground mine, which is now underway.
|
|
|
|
Development of the Company's Mount Morgan Mine Project in Queensland
will add 30,000-35,000 oz of annual gold production and has all
requisite approvals subject to suitable funding. Mount Morgan can be
in production within 12 months.
|
|
|
|
Completion of Homestead and Mount Morgan mines will take total
annual gold production to 230,000 - 250,000 oz at a projected cash
cost of less than A$650/oz.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
NovaGold Resources Inc.
|
|
|
Ticker Symbol & Exchange:
|
|
NG: NYSE -AMEX & TSX
|
|
|
Investor Relations Contact:
|
|
Ariadna Peretz
|
|
|
Investor Relations Contact Phone:
|
|
604-669-6227 ext. 126
|
|
|
Web:
|
|
www.novagold.com
|
|
|
Date of Presentation:
|
|
Friday, September 11, 2009
|
|
|
|
|
|
|
|
NovaGold Resources Inc. (NYSE-AMEX, TSX: NG) is a growth company
focused on gold exploration, development and mining. The Company has
one of the largest reserve/resource bases in the world relative to
its peers, located entirely in North America. Over the course of 10
years NovaGold has acquired and systematically advanced a portfolio
of projects to create shareholder value. NovaGold's resource base
has grown from 500,000 ounces of gold in 1998 to 24 million ounces
of P&P and M&I and more than 5 million ounces of Inferred resource.
The growth and success comes from NovaGold's experienced exploration
team and its ability to forge collaborative partnerships with Native
Alaskan and First Nations groups, local communities, major mining
companies and regulators.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
Novelos Therapeutics, Inc.
|
|
|
Ticker Symbol & Exchange:
|
|
NVLT OTCBB
|
|
|
Investor Relations Contact:
|
|
Stephen Lichaw
|
|
|
Investor Relations Contact Phone:
|
|
201-240-3200
|
|
|
Web:
|
|
www.novelos.com
|
|
|
Date of Presentation:
|
|
November 9, 2009, 4:30pm
|
|
|
|
|
|
|
|
Novelos Therapeutics, Inc. is a biopharmaceutical company
commercializing oxidized glutathione-based compounds for the
treatment of cancer and hepatitis. NOV-002, the lead compound
currently in Phase 3 development for lung cancer under SPA and Fast
Track, acts together with chemotherapy as a chemopotentiator and a
chemoprotectant. NOV-002 is also in Phase 2 development for
early-stage breast cancer and chemotherapy-resistant ovarian cancer.
Novelos has a partnership with Mundipharma to develop and
commercialize NOV-002 in Europe and Japan. Novelos' second compound,
NOV-205, acts as a hepatoprotective agent with immunomodulating and
anti-inflammatory properties. NOV-205 is in Phase 1b development for
chronic hepatitis C non-responders. Both compounds have been
partnered with Lee's Pharm in China.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
NPS Pharmaceuticals
|
|
|
Ticker Symbol & Exchange:
|
|
NPSP - NASDAQ
|
|
|
Investor Relations Contact:
|
|
Susan Mesco
|
|
|
Investor Relations Contact Phone:
|
|
908-450-5516
|
|
|
Web:
|
|
www.npsp.com
|
|
|
Date of Presentation:
|
|
09/10/09
|
|
|
|
|
|
|
|
NPS Pharmaceuticals (Nasdaq: NPSP) is developing new treatment
options for patients with rare gastrointestinal and endocrine
disorders with clear unmet medical needs. The company is currently
conducting two Phase 3 registration studies. Teduglutide, a
proprietary analog of GLP-2, is being evaluated as GATTEX in a
Phase 3 registration study known as STEPS for intestinal failure
associated with short bowel syndrome and in preclinical development
for gastrointestinal mucositis and other pediatric indications.
NPSP558 (parathyroid hormone 1-84 [rDNA origin] injection) is being
evaluated in a Phase 3 registration study known as REPLACE as a
hormone replacement therapy for hypoparathyroidism. NPS complements
its proprietary programs with a royalty-based portfolio of products
and product candidates.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
Ocean Power Technologies, Inc.
|
|
|
Ticker Symbol & Exchange:
|
|
OPTT
|
|
|
Investor Relations Contact:
|
|
Charles F. Dunleavy
|
|
|
Investor Relations Contact Phone:
|
|
609-730-0400
|
|
|
Web:
|
|
www.oceanpowertechnologies.com
|
|
|
Date of Presentation:
|
|
07/10/09
|
|
|
|
|
|
|
|
Ocean Power Technologies is a pioneer in wave energy technology,
with in-ocean experience over 10 years. The Company's proprietary
PowerBuoy system is based on modular, ocean-going buoys that
capture and convert predictable wave energy into low-cost, clean
electricity. The high value added "smart part" of the system enables
the systems to automatically tune their performance to changing wave
conditions. The Company's fundamental business plan is to sell
turn-key power stations, plus operating and maintenance service
contracts over the life-cycle of the plants. Current customers
include the US Navy, Iberdrola SA, the Scottish Government, US DoE
and PNGC Power.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
OctoPlus N.V.
|
|
|
Ticker Symbol & Exchange:
|
|
OCTO (Amsterdam)
|
|
|
Investor Relations Contact:
|
|
Ms. Rianne Roukema
|
|
|
Investor Relations Contact Phone:
|
|
31-71-5241071
|
|
|
Web:
|
|
www.octoplus.nl
|
|
|
Date of Presentation:
|
|
09/11/09
|
|
|
|
|
|
|
|
OctoPlus is a drug product development company that is globally
renowned as a center of excellence in pharmaceutical development and
drug delivery. We offer proven and reliable services in formulation
development, analytical development, process development and GMP
manufacturing. Our expertise is focused on formulation of
biotech-derived compounds and small chemical molecules. In addition,
we offer clients our expertise in combination with our drug delivery
technologies for the development of controlled release formulations
of injectable compounds. Such depot formulation products have
demonstrated strong improvement of side effect profiles, greatly
increased patient compliance and better efficacy.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
On Track Innovations LTD
|
|
|
Ticker Symbol & Exchange:
|
|
NASDAQ GM: OTIV
|
|
|
Investor Relations Contact:
|
|
Galit Mendelson/ Miri Segal
|
|
|
Investor Relations Contact Phone:
|
|
1-201-944-5200/1-917-607-8654
|
|
|
Web:
|
|
www.otiglobal.com
|
|
|
Date of Presentation:
|
|
09/09/09
|
|
|
|
|
|
|
|
On Track Innovations Ltd. (OTI), established in 1990, is a global
leader in contactless smart card solutions for homeland security,
payments, electronic passports, national IDs, petroleum payments and
other applications. OTI's technology offers commercially available,
field-proven,contactless solutions, based on OTI's significant
patents and intellectual property covering the entire value chain.
OTI delivers cards, readers, operating systems and complete
solutions that are scaleable, offering high functionality, security
and flexibility. The Company generates diversified revenue mix from
products, services, licensing and transaction fees and has blue chip
client base.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
OncoGenex Pharmaceuticals
|
|
|
Ticker Symbol & Exchange:
|
|
OGXI
|
|
|
Investor Relations Contact:
|
|
Jason Spark
|
|
|
Investor Relations Contact Phone:
|
|
(619) 849-6005
|
|
|
Web:
|
|
www.oncogenex.com
|
|
|
Date of Presentation:
|
|
September 10, 2009 at 12:30 p.m. ET
|
|
|
|
|
|
|
|
OncoGenex is a biopharmaceutical company committed to the
development and commercialization of new therapies that address
unmet needs in the treatment of cancer. OncoGenex has a deep
oncology pipeline, with each product candidate having a distinct
mechanism of action and representing a unique opportunity for cancer
drug development. OGX-011, the lead candidate that has completed
five Phase 2 clinical studies in prostate, lung and breast cancers,
is designed to inhibit the production of a specific protein
associated with treatment resistance; OGX-427 is in Phase 1 clinical
development; SN2310 has completed the Phase 1 clinical trial; and
CSP-9222 and OGX-225 are currently in pre-clinical development.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
Oncolytics Biotech Inc.
|
|
|
Ticker Symbol & Exchange:
|
|
TSX:ONC, NASDAQ:ONCY
|
|
|
Investor Relations Contact:
|
|
Cathy Ward
|
|
|
Investor Relations Contact Phone:
|
|
403.670.7370
|
|
|
Web:
|
|
www.oncolyticsbiotech.com
|
|
|
Date of Presentation:
|
|
09/10/09
|
|
|
|
|
|
|
|
Oncolytics Biotech Inc. is conducting clinical trials in the U.S.
and the U.K. with the objective of developing REOLYSIN as a human
cancer therapeutic. The current clinical program includes seven
Phase I/II or Phase II human trials examining REOLYSIN alone or in
combination with chemotherapy.
|
|
|
|
This clinical program is designed to identify targets for
late-stage registration trials with REOLYSIN, the first of which
is planned to be a Phase III combination REOLYSIN and
paclitaxel/carboplatin trial for patients with platinum-failed
head and neck cancers.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
Oramed Pharmaceuticals
|
|
|
Ticker Symbol & Exchange:
|
|
OTC: ORMP
|
|
|
Investor Relations Contact:
|
|
Tara Horn
|
|
|
Investor Relations Contact Phone:
|
|
1-646-240-4193
|
|
|
Web:
|
|
www.oramed.com
|
|
|
Date of Presentation:
|
|
Friday September 11, 2009
|
|
|
|
|
|
|
|
Oramed Pharmaceuticals is a technology pioneer in the field of oral
delivery solutions for drugs and vaccines presently delivered via
injection. Oramed is seeking to revolutionize the treatment of
diabetes through its patented flagship product, an orally ingestible
insulin capsule currently in phase 2 clinical trials. Established in
2006, Oramed's technology is based on over 25 years of research by
top research scientists at Jerusalem's Hadassah Medical Center. The
Company's corporate and R&D headquarters are based in
Jerusalem.Oramed's pipeline currently consists of an insulin
suppository (ORMD-0802) and an oral method for delivery of GLP1
analog (ORMD-0901) and the influenza vaccine (ORMD-1001). Oramed's
unique oral delivery technology serves as a platform for other
vaccines and medications currently available exclusively in
injection.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
Orexo
|
|
|
Ticker Symbol & Exchange:
|
|
STO: ORX
|
|
|
Investor Relations Contact:
|
|
Johan Andersson
|
|
|
Investor Relations Contact Phone:
|
|
46 702 100 451
|
|
|
Web:
|
|
www.orexo.com
|
|
|
Date of Presentation:
|
|
09/09/09
|
|
|
|
|
|
|
|
Orexo is a Swedish pharmaceutical company with a focus on the
therapeutic areas of pain and inflammation. Orexo's first
proprietary developed drug, Abstral, for the treatment of
breakthrough pain in cancer patients was launched in Europe in 2008.
The second drug, Edluar - for the short-term treatment of insomnia
was recently launched in the USA. Orexo has a number of projects in
the pipeline and also markets two diagnostic products for the
gastric ulcer bacteria, Helicobacter pylori, through its Kibion
subsidiary.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
Orient Paper Inc.
|
|
|
Ticker Symbol & Exchange:
|
|
OTC BB: OPAI
|
|
|
Investor Relations Contact:
|
|
Winston Yen, CFO
|
|
|
Investor Relations Contact Phone:
|
|
Crocker Coulson, CCG, 1(646) 213-1915
|
|
|
Web:
|
|
www.orientalpapercorporation.com
|
|
|
Date of Presentation:
|
|
5:45PM on Thurs, Sept. 10, 2009
|
|
|
|
|
|
|
|
Orient Paper, Inc., through its wholly owned subsidiaries, Shengde
Holdings, Inc. and Baoding Shengde Paper Co., Ltd., controls and
operates Hebei Baoding Orient Paper Milling Co., Ltd ("HBOP").
Founded in 1996, HBOP is engaged in the production and distribution
of products such as printing paper, uncoated and coated paper,
corrugated paper, plastic paper, graphic design paper, and other
paper and packaging-related products in China. The Company uses
recycled paper as its primary raw material. As one of the largest
paper producers in Hebei Province, China, the Company is
strategically located in Baoding, a city in close proximity to
Beijing where the majority of publishing houses are based. Orient
Paper is committed to diversifying the Company's product offering
and delivering tailored services to its customers.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
Osteologix, Inc.
|
|
|
Ticker Symbol & Exchange:
|
|
OLGX: OTCBB
|
|
|
Investor Relations Contact:
|
|
Baxter Phillips, III
|
|
|
Investor Relations Contact Phone:
|
|
804-747-6026
|
|
|
Web:
|
|
www.osteologix.com
|
|
|
Date of Presentation:
|
|
Wednesday, September 9, 2009
|
|
|
|
|
|
|
|
Osteologix is a specialty biopharmaceutical company committed to
improving the health of those afflicted with musculoskeletal
diseases such as osteoporosis. Its lead investigational product
candidate, NB S101, is a novel pharmaceutical agent for the
treatment and prevention of osteoporosis. For more information
please visit www.osteologix.com.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
Oxygen Biotherapeutics, Inc.
|
|
|
Ticker Symbol & Exchange:
|
|
OXBO OTCBB
|
|
|
Investor Relations Contact:
|
|
Abe Wischnia
|
|
|
Investor Relations Contact Phone:
|
|
619-795-2345
|
|
|
Web:
|
|
www.oxybiomed.com
|
|
|
Date of Presentation:
|
|
Sept. 9, 2009
|
|
|
|
|
|
|
|
Oxygen Biotherapeutics, Inc. is dedicated to commercializing
innovative pharmaceuticals and medical devices in the field of
oxygen therapeutics and Defense Medicine . The company has under
development a perfluorocarbon (PFC) therapeutic oxygen carrier and
liquid ventilation product (Oxycyte) and has out-licensed an
implantable glucose sensor. Core technologies include biomedical
applications for PFCs and medical and industrial applications for
biosensors. Each product candidate is designed with advantages over
currently marketed products in major markets including traumatic
brain injury, sickle cell crisis, trauma, wound care, decompression
sickness, acute respiratory distress syndrome, stroke, myocardial
infarction, surgery, diabetes wounds and ulcers, and cosmetic
applications.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
Pacific Asia Petroleum, Inc.
|
|
|
Ticker Symbol & Exchange:
|
|
PFAP
|
|
|
Investor Relations Contact:
|
|
John Liviakis / Michael Bayes
|
|
|
Investor Relations Contact Phone:
|
|
415-389-4670
|
|
|
Web:
|
|
www.papetroleum.com
|
|
|
Date of Presentation:
|
|
09/11/09
|
|
|
|
|
|
|
|
Pacific Asia Petroleum is an energy company focused on low-risk,
high-return development and production stage opportunities. The
Company is primarily engaged in the business of oil and gas
development, production and distribution in Pacific Rim countries,
with an initial focus on China. It is a strategic partner with
several major energy companies in high-value oil and gas fields in
China. It was founded in 2005 by a group of senior Texaco
executives and is led by CEO Frank Ingriselli. Pacific Asia is a
publicly traded US headquartered company with executive offices in
New York and offices in Beijing and California.
|
|
|
|
|
|
|
|
|
|
|
|
Company:
|
|
PAION AG
|
|
|
Ticker Symbol & Exchange:
|
|
PA8
|
|
|
Investor Relations Contact:
|
|
Ralf Penner
|
|
|
Investor Relations Contact Phone:
|
|
49-2414453152
|
|
|
Web:
|
|
www.paion.com
|
|
|
Date of Presenta |
Search News
Daily News
